Mats Karlsson

Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit.

Arrington, Leticia; van Dijkman, Sven C; Plan, Elodie L.; Karlsson, Mats O.

Part of CPT, 2025

• DOI for Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit.

Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients

Vongjarudech, Thanakorn; Dosne, Anne-Gaelle; Remmerie, Bart; Dooley, Kelly E. et al.

Part of International Journal of Antimicrobial Agents, 2025

• DOI for Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients
• Download full text (pdf) of Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients

Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials

Haem, Elham; Karlsson, Mats O.; Ueckert, Sebastian

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2025

• DOI for Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials
• Download full text (pdf) of Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials

Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models

Arrington, Leticia; Karlsson, Mats

Part of AAPS Journal, 2024

• DOI for Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models
• Download full text (pdf) of Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models

Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia

Dam, Merete; Centanni, Maddalena; Friberg, Lena E.; Centanni, Daniel et al.

Part of Leukemia, p. 712-719, 2024

• DOI for Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia
• Download full text (pdf) of Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia

Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit.

Arrington, Leticia; van Dijkman, Sven C; Plan, Elodie L.; Karlsson, Mats O.

Part of CPT, 2025

• DOI for Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit.

Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients

Vongjarudech, Thanakorn; Dosne, Anne-Gaelle; Remmerie, Bart; Dooley, Kelly E. et al.

Part of International Journal of Antimicrobial Agents, 2025

• DOI for Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients
• Download full text (pdf) of Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients

Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials

Haem, Elham; Karlsson, Mats O.; Ueckert, Sebastian

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2025

• DOI for Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials
• Download full text (pdf) of Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials

Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models

Arrington, Leticia; Karlsson, Mats

Part of AAPS Journal, 2024

• DOI for Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models
• Download full text (pdf) of Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models

Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia

Dam, Merete; Centanni, Maddalena; Friberg, Lena E.; Centanni, Daniel et al.

Part of Leukemia, p. 712-719, 2024

• DOI for Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia
• Download full text (pdf) of Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia

Evaluation of model-integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods

Bjugård Nyberg, Henrik; Chen, Xiaomei; Donnelly, Mark; Fang, Lanyan et al.

Part of CPT, p. 1748-1761, 2024

• DOI for Evaluation of model-integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods
• Download full text (pdf) of Evaluation of model-integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods

Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Lin, Yu‐Jou; van der Laan, Louvina E.; Karlsson, Mats O.; Garcia‐Prats, Anthony J. et al.

Part of Clinical Pharmacology and Therapeutics, 2024

• DOI for Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis
• Download full text (pdf) of Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

A fully automatic tool for development of population pharmacokinetic models

Chen, Xiaomei; Nordgren, Rikard; Belin, Stella; Hamdan, Alzahra et al.

Part of CPT, p. 1784-1797, 2024

• DOI for A fully automatic tool for development of population pharmacokinetic models
• Download full text (pdf) of A fully automatic tool for development of population pharmacokinetic models

Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory

Gewily, Mohamed; Plan, Elodie L.; Yousefi, Elham; König, Franz et al.

Part of Movement Disorders, 2024

• DOI for Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory
• Download full text (pdf) of Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory

Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy

Centanni, Maddalena; Nijhuis, Janine; Karlsson, Mats O.; Friberg, Lena E.

Part of PharmacoEconomics (Auckland), 2024

• DOI for Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy
• Download full text (pdf) of Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy

Longitudinal Analysis of Natural History Progression of Rare and Ultra‐Rare Cerebellar Ataxias Using Item Response Theory

Hamdan, Alzahra; Hendrickx, Niels; Hooker, Andrew C.; Chen, Xiaomei et al.

Part of Clinical Pharmacology and Therapeutics, p. 1593-1605, 2024

• DOI for Longitudinal Analysis of Natural History Progression of Rare and Ultra‐Rare Cerebellar Ataxias Using Item Response Theory
• Download full text (pdf) of Longitudinal Analysis of Natural History Progression of Rare and Ultra‐Rare Cerebellar Ataxias Using Item Response Theory

Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic end points

Chen, Xiaomei; Bjugård Nyberg, Henrik; Donnelly, Mark; Zhao, Liang et al.

Part of CPT, p. 1734-1747, 2024

• DOI for Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic end points
• Download full text (pdf) of Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic end points

A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB

Lin, Yu-Jou; Zou, Yuanxi; Karlsson, Mats O.; Svensson, Elin

Part of Journal of Antimicrobial Chemotherapy, p. 2561-2569, 2024

• DOI for A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB

Efficiency of multivariate tests in trials in progressive supranuclear palsy

Yousefi, Elham; Gewily, Mohamed; Koenig, Franz; Hoeglinger, Guenter et al.

Part of Scientific Reports, 2024

• DOI for Efficiency of multivariate tests in trials in progressive supranuclear palsy
• Download full text (pdf) of Efficiency of multivariate tests in trials in progressive supranuclear palsy

Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea

Wellhagen, Gustaf; Karlsson, Mats O.; Kjellsson, Maria C.; Garmann, Dirk et al.

Part of CPT, p. 880-890, 2024

• DOI for Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea
• Download full text (pdf) of Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea

Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias

Hamdan, Alzahra; Hooker, Andrew C.; Chen, Xiaomei; Traschütz, Andreas et al.

Part of CPT, p. 1327-1340, 2024

• DOI for Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias
• Download full text (pdf) of Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias

Pharmacogenetic testing or Therapeutic Drug Monitoring: A Quantitative Framework

Centanni, Maddalena; Reijnhout, Niels; Thijs, Abel; Karlsson, Mats O. et al.

Part of Clinical Pharmacokinetics, p. 871-884, 2024

• DOI for Pharmacogenetic testing or Therapeutic Drug Monitoring: A Quantitative Framework
• Download full text (pdf) of Pharmacogenetic testing or Therapeutic Drug Monitoring: A Quantitative Framework

Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children

Centanni, Maddalena; Zaher, Omar; Elhad, David; Karlsson, Mats O. et al.

Part of Cancer Chemotherapy and Pharmacology, p. 297-310, 2024

• DOI for Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children
• Download full text (pdf) of Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children

Evaluation of covariate effects in item response theory models

Wellhagen, Gustaf; Yassen, Ashraf; Garmann, Dirk; Broeker, Astrid et al.

Part of CPT, p. 812-822, 2024

• DOI for Evaluation of covariate effects in item response theory models
• Download full text (pdf) of Evaluation of covariate effects in item response theory models

Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis

Thorsted, Anders; Zecchin, Chiara; Berges, Alienor; Karlsson, Mats O. et al.

Part of Clinical Pharmacology and Therapeutics, p. 703-715, 2024

• DOI for Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis
• Download full text (pdf) of Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis

Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis

Centanni, Maddalena; van de Velde, Mirjam E.; Uittenboogaard, Aniek; Kaspers, Gertjan J. L. et al.

Part of Clinical Pharmacokinetics, p. 197-209, 2024

• DOI for Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis
• Download full text (pdf) of Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis

Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach

Brekkan, Ari; Lledo-Garcia, Rocio; Lacroix, Brigitte; Jonsson, Siv et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 65-75, 2024

• DOI for Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach
• Download full text (pdf) of Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach

Properties of the full random-effect modeling approach with missing covariate data

Nyberg, Joakim; Jonsson, E. Niclas; Karlsson, Mats O.; Häggström, Jonas

Part of Statistics in Medicine, p. 935-952, 2024

• DOI for Properties of the full random-effect modeling approach with missing covariate data
• Download full text (pdf) of Properties of the full random-effect modeling approach with missing covariate data

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A

Bukkems, Laura H.; Versloot, Olav; Cnossen, Marjon H.; Jönsson, Siv et al.

Part of Thrombosis and Haemostasis, p. 317-325, 2023

• DOI for Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
• Download full text (pdf) of Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A

Training the next generation of pharmacometric modelers: a multisector perspective

Bonate, Peter L.; Barrett, Jeffrey S.; Ait-Oudhia, Sihem; Brundage, Richard et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 5-31, 2023

• DOI for Training the next generation of pharmacometric modelers: a multisector perspective

Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic-pharmacodynamic models

Ibrahim, Eman; Karlsson, Mats; Friberg, Lena

Part of CPT, p. 1305-1318, 2023

• DOI for Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic-pharmacodynamic models
• Download full text (pdf) of Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic-pharmacodynamic models

Generation and application of avatars in pharmacometric modelling

Chasseloup, Estelle; Hooker, Andrew; Karlsson, Mats

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 411-423, 2023

• DOI for Generation and application of avatars in pharmacometric modelling
• Download full text (pdf) of Generation and application of avatars in pharmacometric modelling

Comparison of Seven Non-Linear Mixed Effect Model-Based Approaches to Test for Treatment Effect

Chasseloup, Estelle; Karlsson, Mats

Part of Pharmaceutics, 2023

• DOI for Comparison of Seven Non-Linear Mixed Effect Model-Based Approaches to Test for Treatment Effect
• Download full text (pdf) of Comparison of Seven Non-Linear Mixed Effect Model-Based Approaches to Test for Treatment Effect

Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine

Chen, Po-Wei; Karlsson, Mats O.; Ueckert, Sebastian; Pritchard-Bell, Ari et al.

Part of CPT, p. 1988-2000, 2023

• DOI for Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine

Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors

Centanni, Maddalena; Thijs, Abel; Desar, Ingrid; Karlsson, Mats O. et al.

Part of Clinical and Translational Science, p. 73-84, 2023

• DOI for Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors
• Download full text (pdf) of Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors

A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer

Liu, Han; Milenković‐Grišić, Ana‐Marija; Krishnan, Sreenath M.; Jönsson, Siv et al.

Part of CPT, p. 1738-1750, 2023

• DOI for A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer
• Download full text (pdf) of A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer

How to Analyze Continuous and Discrete Repeated Measures in Small-Sample Cross-Over Trials?

Verbeeck, Johan; Geroldinger, Martin; Thiel, Konstantin; Hooker, Andrew Craig et al.

Part of Biometrics, p. 3998-4011, 2023

• DOI for How to Analyze Continuous and Discrete Repeated Measures in Small-Sample Cross-Over Trials?

Joint longitudinal model-based meta-analysis of FEV₁ and exacerbation rate in randomized COPD trials

Llanos-Paez, Carolina; Ambery, Claire; Yang, Shuying; Beerahee, Misba et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 297-314, 2023

• DOI for Joint longitudinal model-based meta-analysis of FEV₁ and exacerbation rate in randomized COPD trials
• Download full text (pdf) of Joint longitudinal model-based meta-analysis of FEV₁ and exacerbation rate in randomized COPD trials

Relationship between factor VIII levels and bleeding for rFVIII-SingleChain in severe hemophilia A: A repeated time-to-event analysis

Bukkems, Laura; Jönsson, Siv; Cnossen, Marjon O.; Karlsson, Mats et al.

Part of CPT, p. 706-718, 2023

• DOI for Relationship between factor VIII levels and bleeding for rFVIII-SingleChain in severe hemophilia A: A repeated time-to-event analysis
• Download full text (pdf) of Relationship between factor VIII levels and bleeding for rFVIII-SingleChain in severe hemophilia A: A repeated time-to-event analysis

Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study

Madathil Krishnan, Sreenath; Friberg, Lena; Mercier, Francois; Zhang, Rong et al.

Part of Clinical Pharmacology and Therapeutics, p. 851-858, 2023

• DOI for Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study
• Download full text (pdf) of Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Swen, JesseJ; van der Wouden, Cathelijne H.; Manson, Lisanne E. N.; Abdullah-Koolmees, Heshu et al.

Part of The Lancet, p. 347-356, 2023

• DOI for A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

Grisic, Ana-Marija; Xiong, Wenyuan; Tanneau, Lénaïg; Jönsson, Siv et al.

Part of Clinical Cancer Research, p. 1363-1371, 2022

• DOI for Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
• Download full text (pdf) of Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline

Tanneau, Lénaïg; Karlsson, Mats; Diacon, Andreas H; Shenje, Justin et al.

Part of Clinical Pharmacokinetics, p. 1177-1185, 2022

• DOI for Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
• Download full text (pdf) of Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline

An introduction of the full random effects model

Yngman, Gunnar; Nyberg, Henrik B.; Nyberg, Joakim; Jonsson, E. Niclas et al.

Part of CPT, p. 149-160, 2022

• DOI for An introduction of the full random effects model
• Download full text (pdf) of An introduction of the full random effects model

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

Sasaki, Tomohiro; Svensson, Elin; Wang, Xiaofeng; Wang, Yanlin et al.

Part of Antimicrobial Agents and Chemotherapy, 2022

• DOI for Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis
• Download full text (pdf) of Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Tanneau, Lénaïg; Karlsson, Mats; Rosenkranz, Susan L.; Cramer, Yoninah S. et al.

Part of Clinical Pharmacology and Therapeutics, p. 873-881, 2022

• DOI for Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens
• Download full text (pdf) of Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia

Dreesen, Erwin; Gijsen, Matthias; Elkayal, Omar; Annaert, Pieter et al.

Part of Journal of Antimicrobial Chemotherapy, p. 2479-2488, 2022

• DOI for Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia

Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling

Zou, Yuanxi; Nedelman, Jerry; Lombardi, Antonio; Pappas, Frances et al.

Part of Clinical Pharmacokinetics, p. 1585-1593, 2022

• DOI for Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling
• Download full text (pdf) of Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling

Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients

Llanos-Paez, Carolina C.; Ambery, Claire; Yang, Shuying; Beerahee, Misba et al.

Part of Pharmaceutical research, p. 1779-1787, 2022

• DOI for Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
• Download full text (pdf) of Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients

Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Lyauk, Yassine Kamal; Jonker, Daniel M.; Hooker, Andrew; Lund, Trine Meldgaard et al.

Part of AAPS Journal, 2021

• DOI for Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
• Download full text (pdf) of Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety

Minichmayr, Iris K.; Karlsson, Mats O.; Jönsson, Siv

Part of Pharmaceutical research, p. 593-605, 2021

• DOI for Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety
• Download full text (pdf) of Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety

Improved numerical stability for the bounded integer model

Ueckert, Sebastian; Karlsson, Mats

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 241-251, 2021

• DOI for Improved numerical stability for the bounded integer model
• Download full text (pdf) of Improved numerical stability for the bounded integer model

A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations

Germovsek, Eva; Hansson, Anna; Karlsson, Mats O.; Westin, Ake et al.

Part of Clinical Pharmacology and Therapeutics, p. 416-423, 2021

• DOI for A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations

Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis

Tanneau, Lénaïg; Svensson, Elin; Rossenu, Stefaan; Karlsson, Mats

Part of CPT, p. 1538-1549, 2021

• DOI for Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis
• Download full text (pdf) of Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis

Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires

Svensson, Robin J.; Ribbing, Jakob; Kotani, Naoki; Dolton, Michael et al.

Part of CPT, p. 1221-1235, 2021

• DOI for Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires
• Download full text (pdf) of Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires

Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel

Krishnan, Sreenath M.; Friberg, Lena E.; Bruno, René; Beyer, Ulrich et al.

Part of CPT, p. 1255-1266, 2021

• DOI for Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel
• Download full text (pdf) of Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel

Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item-score models

Chen, Chao; Jönsson, Siv; Yang, Shuying; Plan, Elodie L. et al.

Part of CPT, p. 309-317, 2021

• DOI for Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item-score models
• Download full text (pdf) of Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item-score models

A general model for cell death and biomarker release from injured tissues

Li, Jingyun; Karlsson, Mats; Sanhajariya, Suchaya; Isbister, Geoffrey K. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 69-82, 2021

• DOI for A general model for cell death and biomarker release from injured tissues

Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial

Llanos-Paez, Carolina; Ambery, Claire; Yang, Shuying; Tabberer, Maggie et al.

Part of AAPS Journal, 2021

• DOI for Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial
• Download full text (pdf) of Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial

Assessing Treatment Effects with Pharmacometric Models: A New Method that Addresses Problems with Standard Assessments

Chasseloup, Estelle; Tessier, Adrien; Karlsson, Mats

Part of AAPS Journal, 2021

• DOI for Assessing Treatment Effects with Pharmacometric Models: A New Method that Addresses Problems with Standard Assessments
• Download full text (pdf) of Assessing Treatment Effects with Pharmacometric Models: A New Method that Addresses Problems with Standard Assessments

An Item Response Theory-Informed Strategy to Model Total Score Data from Composite Scales

Wellhagen, Gustaf; Ueckert, Sebastian; Kjellsson, Maria C.; Karlsson, Mats

Part of AAPS Journal, 2021

• DOI for An Item Response Theory-Informed Strategy to Model Total Score Data from Composite Scales
• Download full text (pdf) of An Item Response Theory-Informed Strategy to Model Total Score Data from Composite Scales

Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial

Garcia-Prats, Anthony J.; Svensson, Elin; Winckler, Jana; Draper, Heather R. et al.

Part of Journal of Antimicrobial Chemotherapy, p. 3237-3246, 2021

• DOI for Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial

Model-Informed Drug Development for Long-Acting Injectable Products: Summary of American College of Clinical Pharmacology Symposium

Sharan, Satish; Fang, Lanyan; Lukacova, Viera; Chen, Xiaomei et al.

Part of Clinical Pharmacology in Drug Development, p. 220-228, 2021

• DOI for Model-Informed Drug Development for Long-Acting Injectable Products: Summary of American College of Clinical Pharmacology Symposium

Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data

Wellhagen, Gustaf J.; Karlsson, Mats O.; Kjellsson, Maria C.

Part of AAPS Journal, 2021

• DOI for Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data
• Download full text (pdf) of Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data

Performance of longitudinal item response theory models in shortened or partial assessments.

Arrington, Leticia; Ueckert, Sebastian; Ahamadi, Malidi; Macha, Sreeraj et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 461-471, 2020

• DOI for Performance of longitudinal item response theory models in shortened or partial assessments.
• Download full text (pdf) of Performance of longitudinal item response theory models in shortened or partial assessments.

Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

Lyauk, Yassine Kamal; Jonker, Daniel M.; Lund, Trine Meldgaard; Hooker, Andrew et al.

Part of AAPS Journal, 2020

• DOI for Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
• Download full text (pdf) of Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis

Tanneau, Lénaïg; Karlsson, Mats O.; Svensson, Elin

Part of British Journal of Clinical Pharmacology, p. 913-922, 2020

• DOI for Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis
• Download full text (pdf) of Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis

Comparison of covariate selection methods with correlated covariates: prior information versus data information, or a mixture of both?

Chasseloup, Estelle; Yngman, Gunnar; Karlsson, Mats

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 485-492, 2020

• DOI for Comparison of covariate selection methods with correlated covariates: prior information versus data information, or a mixture of both?

Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework

Netterberg, Ida; Karlsson, Mats; Terstappen, Leon W. M. M.; Koopman, Miriam et al.

Part of Clinical Cancer Research, p. 4892-4900, 2020

• DOI for Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework

A longitudinal item response model for Aberrant Behavior Checklist (ABC) data from children with autism

Haem, Elham; Doostfatemeh, Marziyeh; Firouzabadi, Negar; Ghazanfari, Nima et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 241-253, 2020

• DOI for A longitudinal item response model for Aberrant Behavior Checklist (ABC) data from children with autism

Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study

van der Wouden, Cathelijne H.; Bohringer, Stefan; Cecchin, Erika; Cheung, Ka-Chun et al.

Part of Pharmacogenetics & Genomics, p. 131-144, 2020

• DOI for Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study
• Download full text (pdf) of Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study

Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients

Abrantes, João A.; Solms, Alexander; Garmann, Dirk; Nielsen, Elisabet I. et al.

Part of Haematologica, p. 1443-1453, 2020

• DOI for Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients
• Download full text (pdf) of Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients

Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients

Arshad, Usman; Ploylearmsaeng, Su-arpa; Karlsson, Mats; Doroshyenko, Oxana et al.

Part of Cancer Chemotherapy and Pharmacology, p. 711-722, 2020

• DOI for Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients
• Download full text (pdf) of Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients

Relating Nicotine Plasma Concentration to Momentary Craving Across Four Nicotine Replacement Therapy Formulations

Germovsek, Eva; Hansson, Anna; Kjellsson, Maria C.; Perez Ruixo, Juan Jose et al.

Part of Clinical Pharmacology and Therapeutics, p. 238-245, 2020

• DOI for Relating Nicotine Plasma Concentration to Momentary Craving Across Four Nicotine Replacement Therapy Formulations

The effect of food on the pharmacokinetics of oral ivermectin

Duthaler, Urs; Leisegang, Rory; Karlsson, Mats; Krähenbühl, Stephan et al.

Part of Journal of Antimicrobial Chemotherapy, p. 438-440, 2020

• DOI for The effect of food on the pharmacokinetics of oral ivermectin

A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6

Thorsted, Anders; Bouchene, Salim; Tano, Eva; Castegren, Markus et al.

Part of PLOS ONE, 2019

• DOI for A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6
• Download full text (pdf) of A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6

Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies

Brekkan, Ari; Lopez-Lazaro, Luis; Plan, Elodie L.; Nyberg, Joakim et al.

Part of AAPS Journal, 2019

• DOI for Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies
• Download full text (pdf) of Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies

Variability Attribution for Automated Model Building

Ibrahim, Moustafa M. A.; Nordgren, Rikard; Kjellsson, Maria C.; Karlsson, Mats O.

Part of AAPS Journal, 2019

• DOI for Variability Attribution for Automated Model Building
• Download full text (pdf) of Variability Attribution for Automated Model Building

Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment

Ibrahim, Moustafa M. A.; Ueckert, Sebastian; Freiberga, Svetlana; Kjellsson, Maria C. et al.

Part of AAPS Journal, 2019

• DOI for Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment
• Download full text (pdf) of Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment

A Bounded Integer Model for Rating and Composite Scale Data

Wellhagen, Gustaf J.; Kjellsson, Maria C.; Karlsson, Mats O.

Part of AAPS Journal, 2019

• DOI for A Bounded Integer Model for Rating and Composite Scale Data
• Download full text (pdf) of A Bounded Integer Model for Rating and Composite Scale Data

A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT (R) Daily Diary Data from COPD Patients

Germovsek, Eva; Ambery, Claire; Yang, Shuying; Beerahee, Misba et al.

Part of AAPS Journal, 2019

• DOI for A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT (R) Daily Diary Data from COPD Patients
• Download full text (pdf) of A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT (R) Daily Diary Data from COPD Patients

Development of visual predictive checks accounting for multimodal parameter distributions in mixture models

Arshad, Usman; Chasseloup, Estelle; Nordgren, Rikard; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 241-250, 2019

• DOI for Development of visual predictive checks accounting for multimodal parameter distributions in mixture models

Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII

Abrantes, João A.; Solms, Alexander; Garmann, Dirk; Nielsen, Elisabet I. et al.

Part of CPT, p. 894-903, 2019

• DOI for Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII
• Download full text (pdf) of Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII

Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib

Niebecker, Ronald; Maas, Hugo; Staab, Alexander; Freiwald, Matthias et al.

Part of CPT, p. 230-239, 2019

• DOI for Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib
• Download full text (pdf) of Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib

Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences

Lippert, Joerg; Burghaus, Rolf; Edginton, Andrea; Frechen, Sebastian et al.

Part of CPT, p. 878-882, 2019

• DOI for Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences
• Download full text (pdf) of Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences

Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM

Brekkan, Ari; Jönsson, Siv; Karlsson, Mats O.; Plan, Elodie L.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 591-604, 2019

• DOI for Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM
• Download full text (pdf) of Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM

Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling

Schalkwijk, Stein; ter Heine, Rob; Colbers, Angela; Capparelli, Edmund et al.

Part of Journal of Antimicrobial Chemotherapy, p. 1348-1356, 2019

• DOI for Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling

Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales

Gottipati, Gopichand; Berges, Alienor C.; Yang, Shuying; Chen, Chao et al.

Part of Pharmaceutical research, 2019

• DOI for Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales
• Download full text (pdf) of Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales

Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics 17 (5):593-606, Sep/Oct 2018, DOI:10.1002/pst.1873

Krause, Andreas; Kloft, Charlotte; Huisinga, Wilhelm; Karlsson, Mats et al.

Part of Pharmaceutical statistics, p. 278-281, 2019

• DOI for Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics 17 (5):593-606, Sep/Oct 2018, DOI:10.1002/pst.1873

Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data

Abrantes, João A.; Jönsson, Siv; Karlsson, Mats; Nielsen, Elisabet I.

Part of British Journal of Clinical Pharmacology, p. 1326-1336, 2019

• DOI for Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data

The Integrated Glucose Insulin Minimal Model: An improved version

Ibrahim, Moustafa M. A.; Largajolli, Anna; Karlsson, Mats; Kjellsson, Maria C.

Part of European Journal of Pharmaceutical Sciences, p. 7-19, 2019

• DOI for The Integrated Glucose Insulin Minimal Model: An improved version

Translation between two models; Application with integrated glucose homeostasis models

Ibrahim, Moustafa M. A.; Largajolli, Anna; Kjellsson, Maria C.; Karlsson, Mats

Part of Pharmaceutical research, 2019

• DOI for Translation between two models; Application with integrated glucose homeostasis models
• Download full text (pdf) of Translation between two models; Application with integrated glucose homeostasis models

Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers

Duthaler, Urs; Suenderhauf, Claudia; Karlsson, Mats O; Hussner, Janine et al.

Part of British Journal of Clinical Pharmacology, p. 626-633, 2019

• DOI for Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers

Population Pharmacokinetic and Pharmacodynamic Properties of Artesunate in Patients with Artemisinin Resistant Infections in Southern Myanmar

Lohy Das, Jesmin; Kyaw, Myat P.; Nyunt, Myat; Chit, Khin et al.

Part of Malaria Journal, 2018

• DOI for Population Pharmacokinetic and Pharmacodynamic Properties of Artesunate in Patients with Artemisinin Resistant Infections in Southern Myanmar
• Download full text (pdf) of Population Pharmacokinetic and Pharmacodynamic Properties of Artesunate in Patients with Artemisinin Resistant Infections in Southern Myanmar

A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim

Brekkan, Ari; Lopez-Lazaro, Luis; Yngman, Gunnar; Plan, Elodie L. et al.

Part of AAPS Journal, 2018

• DOI for A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
• Download full text (pdf) of A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim

Model-Based Residual Post-Processing for Residual Model Identification

Ibrahim, Moustafa M. A.; Nordgren, Rikard; Kjellsson, Maria C.; Karlsson, Mats O

Part of AAPS Journal, 2018

• DOI for Model-Based Residual Post-Processing for Residual Model Identification
• Download full text (pdf) of Model-Based Residual Post-Processing for Residual Model Identification

Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology

Pierrillas, Philippe B.; Fouliard, Sylvain; Chenel, Marylore; Hooker, Andrew et al.

Part of AAPS Journal, 2018

• DOI for Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology
• Download full text (pdf) of Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology

Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes

Wellhagen, Gustaf J.; Karlsson, Mats O.; Kjellsson, Maria C.

Part of CPT, p. 331-341, 2018

• DOI for Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes

The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.

Netterberg, Ida; Karlsson, Mats O; Nielsen, Elisabet I.; Quartino, Angelica L et al.

Part of British Journal of Clinical Pharmacology, p. 490-500, 2018

• DOI for The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.

A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat

Bouchene, Salim; Marchand, Sandrine; Couet, William; Friberg, Lena E et al.

Part of Basic & Clinical Pharmacology & Toxicology, p. 407-422, 2018

• DOI for A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat

Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in humans

Guiastrennec, Benjamin; Sonne, David P.; Bergstrand, Martin; Vilsbøll, Tina et al.

Part of CPT, p. 603-612, 2018

• DOI for Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in humans
• Download full text (pdf) of Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in humans

Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests

Ibrahim, Moustafa M. A.; Ghadzi, Siti Maisharah Sheikh; Kjellsson, Maria C.; Karlsson, Mats O.

Part of CPT, p. 432-441, 2018

• DOI for Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests
• Download full text (pdf) of Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests

Pharmacometric analysis of the relationship between absolute lymphocyte count, and expanded disability status scale and relapse rate, efficacy end points, in multiple sclerosis trials

Novakovic, Ana M.; Thorsted, Anders; Schindler, Emilie; Jönsson, Siv et al.

Part of Journal of clinical pharmacology, p. 1284-1294, 2018

• DOI for Pharmacometric analysis of the relationship between absolute lymphocyte count, and expanded disability status scale and relapse rate, efficacy end points, in multiple sclerosis trials

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy

Svensson, Elin; Yngman, Gunnar; Denti, Paolo; McIlleron, Helen et al.

Part of Clinical Pharmacokinetics, p. 591-599, 2018

• DOI for Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
• Download full text (pdf) of Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy

A pharmacometric analysis of patient-reported outcomes in breast cancer patients through item response theory

Schindler, Emilie; Friberg, Lena; Lum, Bertram L.; Wang, Bei et al.

Part of Pharmaceutical research, 2018

• DOI for A pharmacometric analysis of patient-reported outcomes in breast cancer patients through item response theory
• Download full text (pdf) of A pharmacometric analysis of patient-reported outcomes in breast cancer patients through item response theory

Reduced and optimized trial designs for drugs described by a target mediated drug disposition model

Brekkan, Ari; Jönsson, Siv; Karlsson, Mats O; Hooker, Andrew

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 637-647, 2018

• DOI for Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
• Download full text (pdf) of Reduced and optimized trial designs for drugs described by a target mediated drug disposition model

Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications

Guiastrennec, Benjamin; Ramachandran, Geetha; Karlsson, Mats O; Kumar, A.K. Hemanth et al.

Part of Clinical Pharmacology and Therapeutics, p. 733-741, 2018

• DOI for Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications
• Download full text (pdf) of Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications

An exposure-response (ER) model relating nicotine plasma concentration to momentary craving across different nicotine replacement therapy (NRT) formulations

Germovsek, Eva; Hansson, Anna; Kjellsson, Maria C.; Ruixo, Juan Jose Perez et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2018

Sample size for detection of drug effect using item level and total score models for Unified Parkinson's Disease Rating Scale data

Jönsson, Siv; Yang, Shuying; Chen, Chao; Plan, Elodie L. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2018

Implicit and efficient handling of missing covariate information using full random effects modelling

Nyberg, Joakim; Karlsson, Mats O; Jonsson, Niclas E.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2018

Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria

Lohy Das, Jesmin; Rulisa, Stephen; de Vries, Peter J.; Mens, Petra F. et al.

Part of Antimicrobial Agents and Chemotherapy, 2018

• DOI for Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria

Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies

Germovsek, Eva; Lutsar, Irja; Kipper, Karin; Karlsson, Mats O et al.

Part of Journal of Antimicrobial Chemotherapy, p. 1908-1916, 2018

• DOI for Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies
• Download full text (pdf) of Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies

Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma

Baverel, Paul G.; White, Nicholas; Vicini, Paolo; Karlsson, Mats O et al.

Part of Clinical Pharmacology and Therapeutics, p. 826-835, 2018

• DOI for Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma

A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption

Back, Hyun-moon; Song, Byungjeong; Pradhan, Sudeep; Chae, Jung-woo et al.

Part of BMC Pharmacology & Toxicology, 2018

• DOI for A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption

Model Description Language (MDL): A Standard for Modeling and Simulation

Smith, Mike K.; Moodie, Stuart L.; Bizzotto, Roberto; Blaudez, Eric et al.

Part of CPT, p. 647-650, 2017

• DOI for Model Description Language (MDL): A Standard for Modeling and Simulation

A Minimal Continuous-Time Markov Pharmacometric Model.

Schindler, Emilie; Karlsson, Mats O.

Part of AAPS Journal, p. 1424-1435, 2017

• DOI for A Minimal Continuous-Time Markov Pharmacometric Model.
• Download full text (pdf) of A Minimal Continuous-Time Markov Pharmacometric Model.

Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis

Novakovic, Ana M.; Krekels, Elke H.J.; Munafo, Alain; Ueckert, Sebastian et al.

Part of AAPS Journal, p. 172-179, 2017

• DOI for Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis
• Download full text (pdf) of Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis

Modeling a Composite Score in Parkinson's Disease Using Item Response Theory

Gottipati, Gopichand; Karlsson, Mats O.; Plan, Elodie L.

Part of AAPS Journal, p. 837-845, 2017

• DOI for Modeling a Composite Score in Parkinson's Disease Using Item Response Theory
• Download full text (pdf) of Modeling a Composite Score in Parkinson's Disease Using Item Response Theory

Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia

Lohy Das, Jesmin; Dondorp, Arjen M.; Nosten, Francois; Aung, Pyae Phyo et al.

Part of AAPS Journal, p. 1842-1854, 2017

• DOI for Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia
• Download full text (pdf) of Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia

Model averaging for robust assessment of QT prolongation by concentration-response analysis

Dosne, Anne-Gaëlle; Bergstrand, Martin; Karlsson, Mats O; Renard, Didier et al.

Part of Statistics in Medicine, p. 3844-3857, 2017

• DOI for Model averaging for robust assessment of QT prolongation by concentration-response analysis

Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia

Krekels, E. H. J.; Novakovic, Ana M.; Vermeulen, A. M.; Friberg, Lena E et al.

Part of CPT, p. 543-551, 2017

• DOI for Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia
• Download full text (pdf) of Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia

Implications for Drug Characterization in Glucose Tolerance Tests Without Insulin: Simulation Study of Power and Predictions Using Model-Based Analysis

Ghadzi, Siti Maisharah Sheikh; Karlsson, Mats O; Kjellsson, Maria C.

Part of CPT, p. 686-694, 2017

• DOI for Implications for Drug Characterization in Glucose Tolerance Tests Without Insulin: Simulation Study of Power and Predictions Using Model-Based Analysis

Model-Based Interspecies Scaling of Glucose Homeostasis

Alskär, Oskar; Karlsson, Mats O.; Kjellsson, Maria C.

Part of CPT, p. 778-786, 2017

• DOI for Model-Based Interspecies Scaling of Glucose Homeostasis
• Download full text (pdf) of Model-Based Interspecies Scaling of Glucose Homeostasis

A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients

Schindler, Emilie; Amantea, Michael A; Karlsson, Mats O; Friberg, Lena E

Part of CPT, p. 373-382, 2017

• DOI for A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients
• Download full text (pdf) of A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

Nguyen, T. H. T.; Mouksassi, M-S; Holford, N.; Al-Huniti, N. et al.

Part of CPT, p. 87-109, 2017

• DOI for Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics
• Download full text (pdf) of Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy

Svensson, Elin M.; Yngman, Gunnar; Denti, Paolo; McIlleron, Helen et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2017

• DOI for Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy

Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring

Netterberg, Ida; Nielsen, Elisabet I.; Friberg, Lena E; Karlsson, Mats O.

Part of Cancer Chemotherapy and Pharmacology, p. 343-353, 2017

• DOI for Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
• Download full text (pdf) of Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring

Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis

Brill, Margreke JE; Svensson, Elin M; Pandie, Mishal; Maartens, Gary et al.

Part of International Journal of Antimicrobial Agents, p. 212-217, 2017

• DOI for Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis
• Download full text (pdf) of Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis

Differentiation and prognosis of healthy subjects, swedds and parkinson's patients using a multi-dimensional item response theory model

van Dijkman, Sven; Ueckert, Sebastian; Plan, Elodie L.; Karlsson, Mats O.

Part of Journal of the Neurological Sciences, p. 97-98, 2017

• DOI for Differentiation and prognosis of healthy subjects, swedds and parkinson's patients using a multi-dimensional item response theory model

Second order Taylor expansion of likelihood-based models

Aoki, Yasunori; Nyberg, Joakim; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2017

Comparison of diagnostics using model-based post-processing for fast automated model building

Ibrahim, Moustafa M. A.; Nordgren, Rikard; Kjellsson, Maria C.; Karlsson, Mats O

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2017

Differentiation between Parkinson's disease patients and SWEDDs based on the MDS-UPDRS

van Dijkman, Sven; Gottipati, Gopichand; Plan, Elodie L.; Karlsson, Mats O

Part of European Journal of Neurology, p. 642-642, 2017

Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB

Svensson, Elin M.; Karlsson, Mats O

Part of Journal of Antimicrobial Chemotherapy, p. 3398-3405, 2017

• DOI for Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB
• Download full text (pdf) of Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB

Mathematical modelling of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 following ingestion of glucose

Røge, Rikke Meldgaard; Bagger, Jonatan I.; Alskär, Oskar; Kristensen, Niels R. et al.

Part of Basic & Clinical Pharmacology & Toxicology, p. 290-297, 2017

• DOI for Mathematical modelling of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 following ingestion of glucose

An Automated Sampling Importance Resampling Procedure For Estimating Parameter Uncertainty

Dosne, Anne-Gaëlle; Bergstrand, Martin; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 509-520, 2017

• DOI for An Automated Sampling Importance Resampling Procedure For Estimating Parameter Uncertainty
• Download full text (pdf) of An Automated Sampling Importance Resampling Procedure For Estimating Parameter Uncertainty

Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar^® in Children with Acute Lymphoblastic Leukemia

Wuerthwein, Gudrun; Lanvers-Kaminsky, Claudia; Hempel, Georg; Gastine, Silke et al.

Part of European journal of drug metabolism and pharmacokinetics, p. 955-963, 2017

• DOI for Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar^® in Children with Acute Lymphoblastic Leukemia

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study

Dorlo, Thomas P. C.; Kip, Anke E.; Younis, Brima M.; Ellis, Sally J. et al.

Part of Journal of Antimicrobial Chemotherapy, p. 3131-3140, 2017

• DOI for Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
• Download full text (pdf) of Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study

A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.

Sadiq, Muhammad W; Nielsen, Elisabet I.; Khachman, Dalia; Conil, Jean-Marie et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 69-79, 2017

• DOI for A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.
• Download full text (pdf) of A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.

Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine

Permala, Jesmin; Tarning, Joel; Nosten, François; White, Nicholas J. et al.

Part of Antimicrobial Agents and Chemotherapy, 2017

• DOI for Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine
• Download full text (pdf) of Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine

Impact of demographics and disease progression on the relationship between glucose and HbA1c

Claussen, Anetta; Möller, Jonas B.; Kristensen, Niels R.; Klim, Sören et al.

Part of European Journal of Pharmaceutical Sciences, p. 417-423, 2017

• DOI for Impact of demographics and disease progression on the relationship between glucose and HbA1c

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

van der Wouden, C. H.; Cambon-Thomsen, A.; Cecchin, E.; Cheung, K. C. et al.

Part of Clinical Pharmacology and Therapeutics, p. 341-358, 2017

• DOI for Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

An Automated Sampling Importance Resampling Procedure For Estimating Parameter Uncertainty

Dosne, Anne-Gaëlle; Bergstrand, M.; Karlsson, Mats O.

Part of Clinical Pharmacology and Therapeutics, 2017

Population pharmacokinetics of cladribine in patients with multiple sclerosis

Savic, Radojka M.; Novakovic, Ana M.; Ekblom, Marianne; Munafo, Alain et al.

Part of Clinical Pharmacokinetics, p. 1245-1253, 2017

• DOI for Population pharmacokinetics of cladribine in patients with multiple sclerosis
• Download full text (pdf) of Population pharmacokinetics of cladribine in patients with multiple sclerosis

Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models

Haem, Elham; Harling, Kajsa; Ayatollahi, Seyyed Mohammad Taghi; Zare, Najaf et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 55-66, 2017

• DOI for Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models

Modeling the Disease Progression from Healthy to Overt Diabetes in ZDSD Rats

Choy, Steve; de Winter, Willem; Karlsson, Mats O.; Kjellsson, Maria C.

Part of AAPS Journal, p. 1203-1212, 2016

• DOI for Modeling the Disease Progression from Healthy to Overt Diabetes in ZDSD Rats

Pharmacokinetic Interactions for Drugs with a Long Half-Life-Evidence for the Need of Model-Based Analysis

Svensson, Elin M.; Acharya, Chayan; Clauson, Björn; Dooley, Kelly E. et al.

Part of AAPS Journal, p. 171-179, 2016

• DOI for Pharmacokinetic Interactions for Drugs with a Long Half-Life-Evidence for the Need of Model-Based Analysis

A Model-Based Longitudinal Meta-Analysis of FEV1 in Randomized COPD Trials

Korell, Julia; Martin, S. W.; Karlsson, Mats O.; Ribbing, Jakob

Part of Clinical Pharmacology and Therapeutics, p. 315-324, 2016

• DOI for A Model-Based Longitudinal Meta-Analysis of FEV1 in Randomized COPD Trials

Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs

Hennig, Stefanie; Svensson, Elin M; Niebecker, Ronald; Fourie, P Bernard et al.

Part of Journal of Antimicrobial Chemotherapy, p. 1330-1340, 2016

• DOI for Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs

Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial

Krekels, Elke H. J.; Niebecker, Ronald; Karlsson, Mats O.; Miller, Raymond et al.

Part of Clinical Pharmacokinetics, p. 1079-1090, 2016

• DOI for Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial

Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin

Svensson, Elin M; Dosne, Anne-Gaëlle; Karlsson, Mats O

Part of CPT, p. 682-691, 2016

• DOI for Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin
• Download full text (pdf) of Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin

Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches.

Møller, J B; Kristensen, N R; Klim, S; Karlsson, Mats O. et al.

Part of CPT, p. 388-9, 2016

• DOI for Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches.

Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism

Nyberg, Joakim; Karlsson, Kristin E.; Jönsson, Siv; Yin, O. Q. P. et al.

Part of CPT, p. 222-232, 2016

• DOI for Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
• Download full text (pdf) of Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism

Weight-HbA1c-Insulin-Glucose Model for Describing Disease Progression of Type 2 Diabetes

Choy, Steve; Kjellsson, Maria; Karlsson, Mats; de Winter, Willem

Part of CPT, p. 11-19, 2016

• DOI for Weight-HbA1c-Insulin-Glucose Model for Describing Disease Progression of Type 2 Diabetes
• Download full text (pdf) of Weight-HbA1c-Insulin-Glucose Model for Describing Disease Progression of Type 2 Diabetes

PK-PD Modeling of Individual Lesion FDG-PET Response to Predict Overall Survival in Patients With Sunitinib-treated Gastrointestinal Stromal Tumor

Schindler, Emilie; Amantea, M. A.; Karlsson, Mats O.; Friberg, L. E.

Part of CPT, p. 173-181, 2016

• DOI for PK-PD Modeling of Individual Lesion FDG-PET Response to Predict Overall Survival in Patients With Sunitinib-treated Gastrointestinal Stromal Tumor
• Download full text (pdf) of PK-PD Modeling of Individual Lesion FDG-PET Response to Predict Overall Survival in Patients With Sunitinib-treated Gastrointestinal Stromal Tumor

Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake

Guiastrennec, Benjamin; Sonne, D. P.; Hansen, M.; Bagger, J. I. et al.

Part of CPT, p. 692-700, 2016

• DOI for Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake
• Download full text (pdf) of Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake

Semi-mechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes

Alskär, Oskar; Bagger, Jonatan I; Røge, Rikke M; Knop, Filip K et al.

Part of Journal of clinical pharmacology, p. 340-348, 2016

• DOI for Semi-mechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes

Improving The Estimation Of Parameter Uncertainty Distributions In Nonlinear Mixed Effects Models Using Sampling Importance Resampling

Dosne, Anne-Gaëlle; Bergstrand, Martin; Harling, Kajsa; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 583-596, 2016

• DOI for Improving The Estimation Of Parameter Uncertainty Distributions In Nonlinear Mixed Effects Models Using Sampling Importance Resampling
• Download full text (pdf) of Improving The Estimation Of Parameter Uncertainty Distributions In Nonlinear Mixed Effects Models Using Sampling Importance Resampling

dOFV distributions: A New Diagnostic For The Adequacy Of Parameter Uncertainty In Nonlinear Mixed-Effects Models Applied To The Bootstrap

Dosne, Anne-Gaëlle; Niebecker, Ronald; Karlsson, Mats O.

Part of Journal Of Pharmacokinetics And Pharmacodynamics, p. 597-608, 2016

• DOI for dOFV distributions: A New Diagnostic For The Adequacy Of Parameter Uncertainty In Nonlinear Mixed-Effects Models Applied To The Bootstrap
• Download full text (pdf) of dOFV distributions: A New Diagnostic For The Adequacy Of Parameter Uncertainty In Nonlinear Mixed-Effects Models Applied To The Bootstrap

BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen

Chae, Jung-woo; Teo, Yi Ling; Ho, Han Kiat; Lee, Jaeyeon et al.

Part of Cancer Chemotherapy and Pharmacology, p. 623-632, 2016

• DOI for BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen

A proof-of-principle example for identifying drug effect from a mechanistic model with a more parsimonious model

Wang, Shijun; Karlsson, Kristin E.; Kjellsson, Maria; Karlsson, Mats O. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2016

Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions

Henin, Emilie; Bergstrand, Martin; Weitschies, Werner; Karlsson, Mats O.

Part of Pharmaceutical research, p. 751-762, 2016

• DOI for Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions

Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group

Bonate, Peter L.; Ahamadi, Malidi; Budha, Nageshwar; de la Pena, Amparo et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 123-135, 2016

• DOI for Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group

A strategy for residual error modeling incorporating scedasticity of variance and distribution shape

Dosne, Anne-Gaëlle; Bergstrand, Martin; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 137-151, 2016

• DOI for A strategy for residual error modeling incorporating scedasticity of variance and distribution shape
• Download full text (pdf) of A strategy for residual error modeling incorporating scedasticity of variance and distribution shape

Approaches for modeling within subject variability in pharmacometric count data analysis: dynamic inter-occasion variability and stochastic differential equations

Deng, Chenhui; Plan, Elodie L.; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 305-314, 2016

• DOI for Approaches for modeling within subject variability in pharmacometric count data analysis: dynamic inter-occasion variability and stochastic differential equations

A diagnostic tool for population models using non-compartmental analysis: The ncappc package for R

Acharya, Chayan; Hooker, Andrew C.; Turkyilmaz, Gulbeyaz Yildiz; Jönsson, Siv et al.

Part of Computer Methods and Programs in Biomedicine, p. 83-93, 2016

• DOI for A diagnostic tool for population models using non-compartmental analysis: The ncappc package for R
• Download full text (pdf) of A diagnostic tool for population models using non-compartmental analysis: The ncappc package for R

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development

Swat, M. J.; Moodie, S.; Wimalaratne, S. M.; Kristensen, N. R. et al.

Part of CPT, p. 316-319, 2015

• DOI for Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development
• Download full text (pdf) of Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development

Covariate analysis using item response theory modelling of expanded disability status scale (EDSS): a case study of cladribine tablets

Novakovic, A.; Krekels, E. H. J.; Savic, R.; Munafo, A. et al.

Part of Multiple Sclerosis Journal, p. 704-705, 2015

Predicting Reductions in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations from FEV1-A Model-Based Meta-Analysis of Literature Data from Controlled Randomized Clinical Trials

Ribbing, Jakob; Korell, Julia; Cerasoli, Frank; Milligan, Peter A. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2015

Estimation of drug receptor occupancy when non-displaceable binding differs between brain regions: extending the simplified reference tissue model

Kågedal, Matts; Varnäs, Katarina; Hooker, Andrew C; Karlsson, Mats O

Part of British Journal of Clinical Pharmacology, p. 116-127, 2015

• DOI for Estimation of drug receptor occupancy when non-displaceable binding differs between brain regions: extending the simplified reference tissue model

Analyzing Patient-Reported Outcomes in Breast Cancer throughItem-Response Theory Pharmacometric Modeling

Schindler, Emilie; Wang, Bei; Lum, Bert; Girish, Sandhya et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2015

• DOI for Analyzing Patient-Reported Outcomes in Breast Cancer throughItem-Response Theory Pharmacometric Modeling

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Svensson, Elin M.; Murray, Stephen; Karlsson, Mats O.; Dooley, Kelly E.

Part of Journal of Antimicrobial Chemotherapy, p. 1106-1114, 2015

• DOI for Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment

Kågedal, Matts; Karlsson, Mats; Hooker, Andrew C

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 211-224, 2015

• DOI for Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment

Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study

Jönsson, Siv; Simonsson, Ulrika S. H.; Miller, Raymond; Karlsson, Mats O.

Part of Journal of clinical pharmacology, p. 1268-1279, 2015

• DOI for Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study

Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution

Clewe, Oskar; Karlsson, Mats O.; Simonsson, Ulrika S. H.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 699-708, 2015

• DOI for Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution
• Download full text (pdf) of Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution

Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism-the Hokusai-VTE phase 3 study

Niebecker, Ronald; Jönsson, Siv; Karlsson, Mats O; Miller, Raymond et al.

Part of British Journal of Clinical Pharmacology, p. 1374-1387, 2015

• DOI for Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism-the Hokusai-VTE phase 3 study

Pharmacokinetic and Pharmacokinetic/ Pharmacodynamic Modeling to Inform Optimal Dose of Vorapaxar

Gheyas, Ferdous; Lee, Junghoon; Chain, Anne; Stone, Julie et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2015

Quantitative Model Diagrams (QMD): A New Perspective in Model Evaluation

Guiastrennec, Benjamin; Keizer, Ron J.; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2015

Handling Underlying Discrete Variables with Mixed Hidden Markov Models in NONMEM

Plan, Elodie L.; Nyberg, Joakim; Bauer, Robert J.; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2015

Interspecies scaling of dynamic glucose and insulin using a mathematical model approach

Alskar, Oskar; Karlsson, Mats O.; Kjellsson, Maria C.

Part of Diabetologia, 2015

A mathematical disease progression model for the effect of diet and exercise in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study (FDPS)

Ghadzi, Siti Maisharah Sheikh; Karlsson, Mats O.; de Mello, V. D.; Uusitupa, M. et al.

Part of Diabetologia, 2015

Characterization of dose-FEV1 response of tralokinumab, an investigational anti-IL13 monoclonal antibody in patients with uncontrolled asthma: a population pharmacokinetic/pharmacodynamic modeling analysis

Baverel, P.; Karlsson, Mats; Agoram, B.; Kantaria, R.

Part of Allergy. European Journal of Allergy and Clinical Immunology, p. 35-35, 2015

• DOI for Characterization of dose-FEV1 response of tralokinumab, an investigational anti-IL13 monoclonal antibody in patients with uncontrolled asthma: a population pharmacokinetic/pharmacodynamic modeling analysis

Concordance between criteria for covariate model building

Hennig, Stefanie; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 109-125, 2014

• DOI for Concordance between criteria for covariate model building

Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling

Quartino, Angelica L.; Karlsson, Mats O.; Lindman, Henrik; Friberg, Lena E.

Part of Pharmaceutical research, p. 3390-3403, 2014

• DOI for Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling

Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients With Certolizumab Pegol

Lacroix, Brigitte; Karlsson, Mats; Friberg, Lena

Part of CPT, p. 1-11, 2014

• DOI for Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients With Certolizumab Pegol

Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches

Møller, J B; Kristensen, N R; Klim, S; Karlsson, Mats O et al.

Part of CPT, 2014

• DOI for Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches

Evaluation of Bias, Precision, Robustness and Runtime for Estimation Methods in NONMEM 7

Johansson, Åsa M.; Ueckert, Sebastian; Plan, Elodie L.; Hooker, Andrew C. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 223-238, 2014

• DOI for Evaluation of Bias, Precision, Robustness and Runtime for Estimation Methods in NONMEM 7

Improved Utilization of ADAS-cog Assessment Data through Item Response Theory based Pharmacometric Modeling

Ueckert, Sebastian; Plan, Elodie L.; Ito, Kaori; Karlsson, Mats O. et al.

Part of Pharmaceutical research, p. 2152-2165, 2014

• DOI for Improved Utilization of ADAS-cog Assessment Data through Item Response Theory based Pharmacometric Modeling
• Download full text (pdf) of Improved Utilization of ADAS-cog Assessment Data through Item Response Theory based Pharmacometric Modeling

Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model

Ernest II, Charles; Nyberg, Joakim; Karlsson, Mats O.; Hooker, Andrew C.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 639-654, 2014

• DOI for Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model
• Download full text (pdf) of Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model

Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection

Svensson, Elin M.; Dooley, Kelly E.; Karlsson, Mats O.

Part of Antimicrobial Agents and Chemotherapy, p. 6406-6412, 2014

• DOI for Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection

Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention

Bergstrand, Martin; Nosten, Francois; Lwin, Khin Maung; Karlsson, Mats O. et al.

Part of Science Translational Medicine, 2014

• DOI for Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention

A linearization approach for the model-based analysis of combined aggregate and individual patient data

Ravva, Patanjali; Karlsson, Mats O.; French, Jonathan L.

Part of Statistics in Medicine, p. 1460-1476, 2014

• DOI for A linearization approach for the model-based analysis of combined aggregate and individual patient data

Use of a linearization approximation facilitating stochastic model building

Svensson, Elin M.; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 153-158, 2014

• DOI for Use of a linearization approximation facilitating stochastic model building
• Download full text (pdf) of Use of a linearization approximation facilitating stochastic model building

Multiple Imputation of Missing Covariates in NONMEM and Evaluation of the Method's Sensitivity to eta-Shrinkage

Johansson, Åsa M.; Karlsson, Mats O.

Part of AAPS Journal, p. 1035-1042, 2013

• DOI for Multiple Imputation of Missing Covariates in NONMEM and Evaluation of the Method's Sensitivity to eta-Shrinkage

Comparison of Methods for Handling Missing Covariate Data

Johansson, Åsa M.; Karlsson, Mats O.

Part of AAPS Journal, p. 1232-1241, 2013

• DOI for Comparison of Methods for Handling Missing Covariate Data

Whole Body Physiologically-Based Pharmacokinetic Model for Colistin and Colistimethate Sodium (CMS) in Six Different Species: Mouse, Rat, Rabbit, Baboon, Pig and Human

Bouchene, Salim; Marchand, Sandrine; Friberg, Lena E.; Björkman, Sven et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2013

Optimizing disease progression study designs for drug effect discrimination

Ueckert, Sebastian; Hennig, Stefanie; Nyberg, Joakim; Karlsson, Mats O. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 587-596, 2013

• DOI for Optimizing disease progression study designs for drug effect discrimination

Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose

Keizer, Ron J; Karlsson, M O; Hooker, Andrew C

Part of CPT, 2013

• DOI for Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose

Comparisons of Analysis Methods for Proof-of-Concept Trials

Karlsson, Kristin E; Vong, Camille; Bergstrand, Martin; Jonsson, E Niclas et al.

Part of CPT, 2013

• DOI for Comparisons of Analysis Methods for Proof-of-Concept Trials

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

Mentré, F; Chenel, M; Comets, E; Grevel, J et al.

Part of CPT, 2013

• DOI for Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

Best practices in population modeling should always be evolving

Karlsson, M O; Mentré, F

Part of CPT, 2013

• DOI for Best practices in population modeling should always be evolving

Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments

Møller, J B; Overgaard, R V; Kjellsson, Maria C; Kristensen, N R et al.

Part of CPT, 2013

• DOI for Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments

PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST

Hansson, E K; Amantea, M A; Westwood, P; Milligan, P A et al.

Part of CPT, 2013

• DOI for PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment

van der Walt, J-S; Hong, Y; Zhang, L; Pfister, M et al.

Part of CPT, 2013

• DOI for A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST

Hansson, E K; Ma, G; Amantea, M A; French, J et al.

Part of CPT, 2013

• DOI for PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST

Modeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claims

Marshall, S F; Hemmings, R; Josephson, F; Karlsson, M O et al.

Part of CPT, 2013

• DOI for Modeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claims

Drug and disease model resources: a consortium to create standards and tools to enhance model-based drug development

Harnisch, L; Matthews, I; Chard, J; Karlsson, M O

Part of CPT, 2013

• DOI for Drug and disease model resources: a consortium to create standards and tools to enhance model-based drug development

A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066-Estimating occupancy in the absence of a reference region

Kågedal, Matts; Cselenyi, Zsolt; Nyberg, Svante; Raboisson, Patrick et al.

Part of NeuroImage, p. 160-169, 2013

• DOI for A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066-Estimating occupancy in the absence of a reference region

Simultaneous optimal experimental design for in vitro binding parameter estimation

Ernest II, Charles Steven; Karlsson, Mats O.; Hooker, Andrew C.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 573-585, 2013

• DOI for Simultaneous optimal experimental design for in vitro binding parameter estimation

Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model

Choy, Steve; Henin, Emilie; van der Walt, Jan-Stefan; Kjellsson, Maria et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 1-10, 2013

• DOI for Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model

A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture

Chigutsa, Emmanuel; Patel, Kashyap; Denti, Paolo; Visser, Marianne et al.

Part of Antimicrobial Agents and Chemotherapy, p. 789-795, 2013

• DOI for A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture

A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A

Frobel, Anne-Kristina; Karlsson, Mats O.; Backman, Janne T.; Hoppu, Kalle et al.

Part of British Journal of Clinical Pharmacology, p. 603-615, 2013

• DOI for A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A

Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin

Zhang, Chao; Denti, Paolo; Decloedt, Eric H.; Ren, Yuan et al.

Part of British Journal of Clinical Pharmacology, p. 741-751, 2013

• DOI for Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin

Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections

Di Paolo, Antonello; Tascini, Carlo; Polillo, Marialuisa; Gemignani, Giulia et al.

Part of International Journal of Antimicrobial Agents, p. 250-255, 2013

• DOI for Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections

Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

Svensson, Elin M.; Aweeka, Francesca; Park, Jeong-Gun; Marzan, Florence et al.

Part of Antimicrobial Agents and Chemotherapy, p. 2780-2787, 2013

• DOI for Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment

Kjellsson, Maria C.; Cosson, Valerie F.; Mazer, Norman A.; Frey, Nicolas et al.

Part of Journal of clinical pharmacology, p. 589-600, 2013

• DOI for A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment

A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects

Lledó-García, Rocío; Mazer, Norman A.; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 129-142, 2013

• DOI for A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects

Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model

Schneck, Karen B.; Zhang, Xin; Bauer, Robert; Karlsson, Mats O. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 67-80, 2013

• DOI for Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model

Benefits of an Item Response Theory Based Analysis of ADAS-cog Assessments

Ueckert, Sebastian; Plan, Elodie L.; Ito, Kaori; Karlsson, Mats O. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2013

Pharmacometric Modeling of Clinical ADAS-cog Assessment Data using Item Response Theory

Ueckert, Sebastian; Plan, Elodie L.; Ito, Kaori; Karlsson, Mats O. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2013

Predicting Baseline ADAS-cog Scores from Screening Information using Item Response Theory and Full Random Effect Covariate Modeling

Ueckert, Sebastian; Plan, Elodie L.; Ito, Kaori; Karlsson, Mats O. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2013

ADOPT (A Dynamic HbA(1c) EndpOint Prediction Tool): A framework for Predicting Primary Endpoint in Phase 3 Diabetes Trials

Moller, Jonas B.; Overgaard, Rune V.; Kjellsson, Maria C.; Kristensen, Niels R. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2013

A Model Predicting Penetration of Rifampicin from Plasma to Epithelial Lining Fluid and Alveolar Cells

Clewe, Oskar; Karlsson, Mats O.; Goutelle, Sylvain; Conte, John E. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2013

A mechanism-Based Approach for Absorption Modeling: The Gastro-Intestinal Transit Time (GITT) Model

Hénin, Emilie; Bergstrand, Martin; Standing, Joseph F.; Karlsson, Mats O.

Part of AAPS Journal, p. 155-163, 2012

• DOI for A mechanism-Based Approach for Absorption Modeling: The Gastro-Intestinal Transit Time (GITT) Model

Rapid Sample Size Calculations for a Defined Likelihood Ratio Test-Based Power in Mixed-Effects Models

Vong, Camille; Bergstrand, Martin; Nyberg, Joakim; Karlsson, Mats O.

Part of AAPS Journal, p. 176-186, 2012

• DOI for Rapid Sample Size Calculations for a Defined Likelihood Ratio Test-Based Power in Mixed-Effects Models

Shrinkage in Nonlinear Mixed-Effects Population Models: Quantification, Influencing Factors, and Impact

Xu, Xu Steven; Yuan, Min; Karlsson, Mats O.; Dunne, Adrian et al.

Part of AAPS Journal, p. 927-936, 2012

• DOI for Shrinkage in Nonlinear Mixed-Effects Population Models: Quantification, Influencing Factors, and Impact

Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models

Plan, Elodie L.; Maloney, Alan; Mentré, France; Karlsson, Mats O. et al.

Part of AAPS Journal, p. 420-432, 2012

• DOI for Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children

Zhang, Chao; McIlleron, Helen; Ren, Yuan; van der Walt, Jan-Stefan et al.

Part of Antiviral Therapy, p. 25-33, 2012

• DOI for Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children

PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool

Nyberg, Joakim; Ueckert, Sebastian; Strömberg, Eric; Hennig, Stefanie et al.

Part of Computer Methods and Programs in Biomedicine, p. 789-805, 2012

• DOI for PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool

Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin

Hennig, Stefanie; Nyberg, Joakim; Fanta, Samuel; Backman, Janne T. et al.

Part of Journal of clinical pharmacology, p. 347-360, 2012

• DOI for Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin

Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults

Friberg, Lena E.; Ravva, Patanjali; Karlsson, Mats O.; Liu, Ping

Part of Antimicrobial Agents and Chemotherapy, p. 3032-3042, 2012

• DOI for Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults

Serial correlation in optimal design for nonlinear mixed effects models

Nyberg, Joakim; Höglund, Richard; Bergstrand, Martin; Karlsson, Mats O. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 239-249, 2012

• DOI for Serial correlation in optimal design for nonlinear mixed effects models

A Semi-mechanistic Modeling Strategy to Link In Vitro and In Vivo Drug Release for Modified Release Formulations

Bergstrand, Martin; Söderlind, Erik; Eriksson, Ulf G; Weitschies, Werner et al.

Part of Pharmaceutical research, p. 695-706, 2012

• DOI for A Semi-mechanistic Modeling Strategy to Link In Vitro and In Vivo Drug Release for Modified Release Formulations

Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodology

Delattre, Maud; Savic, Radojka M.; Miller, Raymond; Karlsson, Mats O. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 263-271, 2012

• DOI for Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodology

A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations

Bergstrand, Martin; Söderlind, Erik; Eriksson, Ulf G; Weitschies, Werner et al.

Part of Pharmaceutical research, p. 574-584, 2012

• DOI for A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations

Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin

Zhang, Chao; Denti, Paolo; Decloedt, Eric; Maartens, Gary et al.

Part of British Journal of Clinical Pharmacology, p. 758-767, 2012

• DOI for Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin

Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers

Kågedal, Matts; Cselényi, Zsolt; Nyberg, Svante; Jönsson, Siv et al.

Part of NeuroImage, p. 849-856, 2012

• DOI for Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers

Influence of CYP2B6 516G > T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children

Viljoen, M.; Karlsson, Mats O; Meyers, T. M.; Gous, H. et al.

Part of European Journal of Clinical Pharmacology, p. 339-347, 2012

• DOI for Influence of CYP2B6 516G > T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children

Population Pharmacokinetics of Busulfan in Children: Response

Trame, Mirjam N.; Bergstrand, Martin; Karlsson, Mats O.; Hempel, Georg

Part of Clinical Cancer Research, p. 2717-2718, 2012

• DOI for Population Pharmacokinetics of Busulfan in Children: Response

Evaluation of IPPSE, an alternative method for sequential population PKPD analysis

Lacroix, Brigitte D.; Friberg, Lena E.; Karlsson, Mats O

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 177-193, 2012

• DOI for Evaluation of IPPSE, an alternative method for sequential population PKPD analysis

Ethically Attractive Dose-Finding Designs for Drugs With a Narrow Therapeutic Index

Lledó-García, Rocío; Hennig, Stefanie; Nyberg, Joakim; Hooker, Andrew C et al.

Part of Journal of clinical pharmacology, p. 29-38, 2012

• DOI for Ethically Attractive Dose-Finding Designs for Drugs With a Narrow Therapeutic Index

Identification of the Mechanism of Action of a Glucokinase Activator From Oral Glucose Tolerance Test Data in Type 2 Diabetic Patients Based on an Integrated Glucose-Insulin Model

Jauslin, Petra; Karlsson, Mats O; Frey, Nicolas

Part of Journal of clinical pharmacology, p. 1861-1871, 2012

• DOI for Identification of the Mechanism of Action of a Glucokinase Activator From Oral Glucose Tolerance Test Data in Type 2 Diabetic Patients Based on an Integrated Glucose-Insulin Model

Pharmacokinetic-Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus

Hamrén, Bengt; Öhman, K Peter; Svensson, Maria K; Karlsson, Mats O.

Part of Journal of clinical pharmacology, p. 1317-1327, 2012

• DOI for Pharmacokinetic-Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus

A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model

Quartino, Angelica; Friberg, Lena E; Karlsson, Mats O

Part of Investigational new drugs, p. 833-845, 2012

• DOI for A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model

Likert Pain Scores Modeling: A Markov Integer Model and an Autoregressive Continuous Model

Plan, Elodie L; Elshoff, Jan-Peer; Stockis, Armel; Sargentini-Maier, Laura et al.

Part of Clinical Pharmacology and Therapeutics, p. 820-828, 2012

• DOI for Likert Pain Scores Modeling: A Markov Integer Model and an Autoregressive Continuous Model

Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment

Ahn, Jae Eun; Plan, Elodie L; Karlsson, Mats O; Miller, Raymond

Part of Journal of clinical pharmacology, p. 880-892, 2012

• DOI for Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment

Population Pharmacokinetic Model for Adherence Evaluation Using Lamivudine Concentration Monitoring

Zhang, Chao; Denti, Paolo; van der Walt, Jan-Stefan; Ren, Yuan et al.

Part of Therapeutic Drug Monitoring, p. 481-484, 2012

• DOI for Population Pharmacokinetic Model for Adherence Evaluation Using Lamivudine Concentration Monitoring

Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics

Svensson, Elin; van der Walt, Jan-Stefan; Barnes, Karen I.; Cohen, Karen et al.

Part of British Journal of Clinical Pharmacology, p. 465-476, 2012

• DOI for Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics

Modeling of red blood cell life-spans in hematologically normal populations

Lledo-Garcia, Rocio; Kalicki, Robert M.; Uehlinger, Dominik E.; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 453-462, 2012

• DOI for Modeling of red blood cell life-spans in hematologically normal populations

Letter to the editor regarding: "A reduction in between subject variability is not mandatory for selecting a new covariate"

Karlsson, Mats O; Bergstrand, Martin

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 725-726, 2012

• DOI for Letter to the editor regarding: "A reduction in between subject variability is not mandatory for selecting a new covariate"

Standard Error of Empirical Bayes Estimate in NONMEM (R) VI

Kang, Dongwoo; Bae, Kyun-Seop; Houk, Brett E.; Savic, Radojka M. et al.

Part of Korean Journal of Physiology & Pharmacology, p. 97-106, 2012

• DOI for Standard Error of Empirical Bayes Estimate in NONMEM (R) VI

Performance of three estimation methods in repeated time-to-event modeling

Karlsson, Kristin E.; Plan, Elodie L.; Karlsson, Mats O.

Part of AAPS Journal, p. 83-91, 2011

• DOI for Performance of three estimation methods in repeated time-to-event modeling

A Fast Method for Testing Covariates in Population PK/PD Models

Khandelwal, Akash; Harling, Kajsa; Jonsson, Niclas E.; Hooker, Andrew C. et al.

Part of AAPS Journal, p. 464-472, 2011

• DOI for A Fast Method for Testing Covariates in Population PK/PD Models

A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion

Westin, Jerker; Nyholm, Dag; Pålhagen, Sven; Willows, Thomas et al.

Part of Clinical neuropharmacology, p. 61-65, 2011

• DOI for A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion

Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance

Wallin, Johan E; Bergstrand, Martin; Wilczek, Henryk E; Nydert, Per S et al.

Part of Therapeutic Drug Monitoring, p. 663-672, 2011

• DOI for Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance

Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.

Trame, Mirjam N; Bergstrand, Martin; Karlsson, Mats O; Boos, Joachim et al.

Part of Clinical Cancer Research, p. 6867-6877, 2011

• DOI for Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.

Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models

Baverel, Paul G.; Savic, Radojka M.; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 63-82, 2011

• DOI for Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models

Modeling sleep data for a new drug in development using Markov mixed-effects models

Kjellsson, Maria C.; Ouellet, Daniele; Corrigan, Brian; Karlsson, Mats O.

Part of Pharmaceutical research, p. 2610-2627, 2011

• DOI for Modeling sleep data for a new drug in development using Markov mixed-effects models

Modeling of 24-Hour Glucose and Insulin Profiles of Patients With Type 2 Diabetes

Jauslin, Petra; Frey, Nicolas; Karlsson, Mats

Part of Journal of clinical pharmacology, p. 153-164, 2011

• DOI for Modeling of 24-Hour Glucose and Insulin Profiles of Patients With Type 2 Diabetes

Transient Lower Esophageal Sphincter Relaxations PKPD Modeling: Count Model and Repeated Time-To-Event Model

Plan, Elodie L; Ma, Guangli; Någård, Mats; Jensen, Jörgen et al.

Part of Journal of Pharmacology and Experimental Therapeutics, 2011

• DOI for Transient Lower Esophageal Sphincter Relaxations PKPD Modeling: Count Model and Repeated Time-To-Event Model

A Population Pharmacokinetic/Pharmacodynamic Model of Methotrexate and Mucositis Scores in Osteosarcoma

Johansson, Åsa M.; Hill, Nicola; Perisoglou, Martha; Whelan, Jeremy et al.

Part of Therapeutic Drug Monitoring, p. 711-718, 2011

• DOI for A Population Pharmacokinetic/Pharmacodynamic Model of Methotrexate and Mucositis Scores in Osteosarcoma

Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales

Karlsson, Kristin E.; Wilkins, Justin J.; Jonsson, Fredrik; Zingmark, Per-Henrik et al.

Part of AAPS Journal, p. 683-691, 2010

• DOI for Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales

Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus

Wilmshurst, Jo M; van der Walt, Jan-Stefan; Ackermann, Sally; Karlsson, Mats O et al.

Part of Journal of Paediatrics and Child Health, p. 17-22, 2010

• DOI for Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus

A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis

Gupta, Pankaj; Friberg, Lena E; Karlsson, Mats O; Krishnaswami, Sriram et al.

Part of Journal of clinical pharmacology, p. 679-687, 2010

• DOI for A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

Keizer, Ron J.; Gupta, Anubha; Mac Gillavry, Melvin R.; Jansen, Mendel et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 347-363, 2010

• DOI for A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression

Hansson, Emma K.; Wallin, Johan; Lindman, Henrik; Sandström, Marie et al.

Part of Cancer Chemotherapy and Pharmacology, p. 839-848, 2010

• DOI for Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression
• Download full text (pdf) of Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression

An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers

Silber, Hanna E.; Frey, Nicolas; Karlsson, Mats O.

Part of Journal of clinical pharmacology, p. 246-256, 2010

• DOI for An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers
• Download full text (pdf) of An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents

Zandvliet, Anthe S.; Karlsson, Mats O.; Schellens, Jan H. M.; Copalu, William et al.

Part of Investigational new drugs, p. 61-75, 2010

• DOI for Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents

Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients

Bizzotto, Roberto; Zamuner, Stefano; De Nicolao, Giuseppe; Karlsson, Mats O. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 137-155, 2010

• DOI for Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients

Methodological Comparison of In Vitro Binding Parameter Estimation: Sequential vs. Simultaneous Non-linear Regression

Ernest, C. Steven; Hooker, Andrew C.; Karlsson, Mats O.

Part of Pharmaceutical research, p. 866-877, 2010

• DOI for Methodological Comparison of In Vitro Binding Parameter Estimation: Sequential vs. Simultaneous Non-linear Regression

Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin

Ma, Guangli; Friberg, Lena E.; Movin-Osswald, Gunilla; Karlsson, Mats O.

Part of British Journal of Clinical Pharmacology, p. 815-824, 2010

• DOI for Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin

Long-Term Changes in Cyclosporine Pharmacokinetics After Renal Transplantation in Children: Evidence for Saturable Presystemic Metabolism and Effect of NR1I2 Polymorphism

Fanta, Samuel; Jönsson, Siv; Karlsson, Mats O.; Niemi, Mikko et al.

Part of Journal of clinical pharmacology, p. 581-597, 2010

• DOI for Long-Term Changes in Cyclosporine Pharmacokinetics After Renal Transplantation in Children: Evidence for Saturable Presystemic Metabolism and Effect of NR1I2 Polymorphism

A two-compartment effect site model describes the bispectral index after different rates of propofol infusion

Björnsson, Marcus A.; Norberg, Ake; Kalman, Sigridur; Karlsson, Mats O. et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 243-255, 2010

• DOI for A two-compartment effect site model describes the bispectral index after different rates of propofol infusion

Approaches to simultaneous analysis of frequency and severity of symptoms

Plan, Elodie L.; Karlsson, Kristin E.; Karlsson, Mats O.

Part of Clinical Pharmacology and Therapeutics, p. 255-259, 2010

• DOI for Approaches to simultaneous analysis of frequency and severity of symptoms

Evaluation of management of hypertension in response to the receptor tyrosine kinase inhibitor, E7080: a modeling and simulation approach

Keizer, R. J.; Gupta, A.; Karlsson, M. O.; Wanders, J. et al.

Part of European Journal of Cancer Supplements, p. 144-144, 2010

• DOI for Evaluation of management of hypertension in response to the receptor tyrosine kinase inhibitor, E7080: a modeling and simulation approach

A Model for Glucose, Insulin, and Beta-Cell Dynamics in Subjects With Insulin Resistance and Patients With Type 2 Diabetes

Ribbing, Jakob; Hamrén, Bengt; Svensson, Maria K.; Karlsson, Mats O.

Part of Journal of clinical pharmacology, p. 861-872, 2010

• DOI for A Model for Glucose, Insulin, and Beta-Cell Dynamics in Subjects With Insulin Resistance and Patients With Type 2 Diabetes

Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM

Petersson, Klas J. F.; Friberg, Lena E.; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 493-506, 2010

• DOI for Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM

Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics

Steimer, Jean-Louis; Dahl, Svein G.; De Alwis, Dinesh P.; Gundert-Remy, Ursula et al.

Part of European Journal of Cancer, p. 21-32, 2010

• DOI for Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics

Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making

Karlsson, Kristin C.; Savić, Radojka M.; Hooker, Andrew C.; Karlsson, Mats O

Part of AAPS Journal, p. 148-154, 2009

• DOI for Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making

Handling data below the limit of quantification in mixed effect models.

Bergstrand, Martin; Karlsson, Mats O.

Part of AAPS Journal, p. 371-380, 2009

• DOI for Handling data below the limit of quantification in mixed effect models.

Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions

Savic, Radojka; Karlsson, Mats

Part of AAPS Journal, p. 558-569, 2009

• DOI for Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions

Evaluation of an Extended Grid Method for Estimation Using Nonparametric Distributions

Savic, Radojka; Karlsson, Mats

Part of AAPS Journal, p. 615-627, 2009

• DOI for Evaluation of an Extended Grid Method for Estimation Using Nonparametric Distributions

Semiparametric Distributions with Estimated Shape Parameters

Petersson, Klas; Hanze, Eva; Savic, Radojka; Karlsson, Mats

Part of Pharmaceutical research, p. 2174-2185, 2009

• DOI for Semiparametric Distributions with Estimated Shape Parameters

Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia

Friberg, Lena; de Greef, R.; Kerbusch, T.; Karlsson, Mats

Part of Clinical Pharmacology and Therapeutics, p. 84-91, 2009

• DOI for Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia

Evaluation of the Nonparametric Estimation Method in NONMEM VI

Savic, Radojka M.; Kjellsson, Maria C.; Karlsson, Mats O.

Part of European Journal of Pharmaceutical Sciences, p. 27-35, 2009

• DOI for Evaluation of the Nonparametric Estimation Method in NONMEM VI

A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis

Lacroix, Brigitte; Karlsson, Mats; Friberg, Lena

Part of Clinical Pharmacology and Therapeutics, p. 387-395, 2009

• DOI for A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis

The time course of body temperature, serum amyloid A protein, C-reactive protein and interleukin-6 in patients with bacterial infection during the initial 3 days of antibiotic therapy

Lannergård, Anders; Viberg, Anders; Cars, Otto; Karlsson, Mats O. et al.

Part of Scandinavian Journal of Infectious Diseases, p. 663-671, 2009

• DOI for The time course of body temperature, serum amyloid A protein, C-reactive protein and interleukin-6 in patients with bacterial infection during the initial 3 days of antibiotic therapy

A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis

Lacroix, B. D.; Lovern, M R; Stockis, A; Sargentini-Maier, M L et al.

Part of Clinical Pharmacology and Therapeutics, p. 387-395, 2009

• DOI for A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis

An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment

Friberg, L. E.; Vermeulen, A. M.; Petersson, K. J. F.; Karlsson, M. O.

Part of Clinical Pharmacology and Therapeutics, p. 409-417, 2009

• DOI for An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment

Performance in population models for count data, part I: maximum likelihood approximations.

Plan, Elodie L.; Maloney, Alan; Trocóniz, Iñaki F.; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 353-366, 2009

• DOI for Performance in population models for count data, part I: maximum likelihood approximations.

Trial treatment length optimization with an emphasis on disease progression studies

Hennig, Stefanie; Nyberg, Joakim; Hooker, Andrew C; Karlsson, Mats O

Part of Journal of clinical pharmacology, p. 323-335, 2009

• DOI for Trial treatment length optimization with an emphasis on disease progression studies

The influence of underlying assumptions on evaluating the relative merits of concentration-controlled and dose-controlled trials

Lledó-García, R.; Hennig, S.; Karlsson, M. O.

Part of Clinical Pharmacology and Therapeutics, p. 70-76, 2009

• DOI for The influence of underlying assumptions on evaluating the relative merits of concentration-controlled and dose-controlled trials

Comparison of dose-finding designs for narrow-therapeutic-index drugs: concentration-controlled vs. dose-controlled trials

Lledó-García, R.; Hennig, S.; Karlsson, M. O.

Part of Clinical Pharmacology and Therapeutics, p. 62-69, 2009

• DOI for Comparison of dose-finding designs for narrow-therapeutic-index drugs: concentration-controlled vs. dose-controlled trials

The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion

Silber, Hanna E; Kjellsson, Maria C; Karlsson, Mats O

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 81-99, 2009

• DOI for The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion

Simultaneous optimal experimental design on dose and sample times

Nyberg, Joakim; Karlsson, Mats O.; Hooker, Andrew C.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 125-145, 2009

• DOI for Simultaneous optimal experimental design on dose and sample times

Evaluation of the Nonparametric Estimation Method in NONMEM VI: Application to Real Data

Baverel, Paul; Savic, Radojka; Wilkins, Justin; Karlsson, Mats

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 297-315, 2009

• DOI for Evaluation of the Nonparametric Estimation Method in NONMEM VI: Application to Real Data

Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design

Silber, Hanna E.; Nyberg, Joakim; Hooker, Andrew C.; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 281-295, 2009

• DOI for Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design
• Download full text (pdf) of Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design

A tool for neutrophil guided dose adaptation in chemotherapy

Wallin, Johan E.; Friberg, Lena E.; Karlsson, Mats O.

Part of Computer Methods and Programs in Biomedicine, p. 283-291, 2009

• DOI for A tool for neutrophil guided dose adaptation in chemotherapy
• Download full text (pdf) of A tool for neutrophil guided dose adaptation in chemotherapy

Modelling overdispersion and Markovian features in count data.

Trocóniz, Iñaki F; Plan, Elodie L.; Miller, Raymond; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 461-477, 2009

• DOI for Modelling overdispersion and Markovian features in count data.

Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics

Bergstrand, Martin; Söderlind, E.; Weitschies, W.; Karlsson, Mats O.

Part of Clinical Pharmacology and Therapeutics, p. 77-83, 2009

• DOI for Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics

A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling

Karlsson, Kristin C.; van de Schootbrugge, Margunn; Eriksen, Heidi Oien; Moberg, Enrica Ratti et al.

Part of Therapeutic Drug Monitoring, p. 86-94, 2009

• DOI for A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling

Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies

Karlsson, Mats O; Lutsar, Irja; Milligan, Peter A

Part of Antimicrobial Agents and Chemotherapy, p. 935-944, 2009

• DOI for Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies

Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements

Hooker, Andrew C; Ten Tije, A J; Carducci, M A; Weber, J et al.

Part of Clinical Pharmacology and Therapeutics, p. 111-118, 2008

• DOI for Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements

Approaches to handling pharmacodynamic baseline responses

Dansirikul, Chantaratsamon; Silber, Hanna E; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 269-283, 2008

• DOI for Approaches to handling pharmacodynamic baseline responses

Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin

Magnusson, M O; Dahl, M-L; Cederberg, J; Karlsson, M O et al.

Part of Clinical Pharmacology and Therapeutics, p. 52-62, 2008

• DOI for Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin

The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data

Tunblad, Karin; Lindbom, Lars; McFadyen, Lynn; Jonsson, E. Niclas et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 503-526, 2008

• DOI for The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data

Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients Including a Semi-mechanistic Model to Describe Variable Absorption

Wilkins, Justin J.; Savic, Radojka M.; Karlsson, Mats O.; Langdon, Grant et al.

Part of Antimicrobial Agents and Chemotherapy, p. 2138-2148, 2008

• DOI for Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients Including a Semi-mechanistic Model to Describe Variable Absorption

A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens

Elsherbiny, Doaa A.; Asimus, Sara A.; Karlsson, Mats O.; Ashton, Michael et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 203-217, 2008

• DOI for A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens

Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function: evidence of interconversion

Hamrén, Bengt; Ericsson, Hans; Samuelsson, Ola; Karlsson, Mats O.

Part of British Journal of Clinical Pharmacology, p. 855-863, 2008

• DOI for Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function: evidence of interconversion

Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment

Hamrén, Bengt; Björk, Elisabeth; Sunzel, Maria; Karlsson, Mats O

Part of Clinical Pharmacology and Therapeutics, p. 228-235, 2008

• DOI for Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment

Comparison of proportional odds and differential odds models for mixed-effects analysis of categorical data

Kjellsson, Maria C.; Zingmark, Per-Henrik; Jonsson, E. Niclas; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 483-501, 2008

• DOI for Comparison of proportional odds and differential odds models for mixed-effects analysis of categorical data

Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues

Tornøe, Christoffer W.; Agersø, Henrik; Senderovitz, Thomas; Nielsen, Henrik A. et al.

Part of British Journal of Clinical Pharmacology, p. 648-664, 2007

• DOI for Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues

Randomized exposure-controlled trials: Impact of randomization and analysis strategies

Karlsson, Kristin E.; Grahnén, Anders; Karlsson, Mats O.; Jonsson, E. Niclas

Part of British Journal of Clinical Pharmacology, p. 266-277, 2007

• DOI for Randomized exposure-controlled trials: Impact of randomization and analysis strategies

Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments

Nielsen, Elisabet I.; Viberg, Anders; Löwdin, Elisabeth; Cars, Otto et al.

Part of Antimicrobial Agents and Chemotherapy, p. 128-136, 2007

• DOI for Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments

Implementation of a Transit Compartment Model for Describing Drug Absorption in Pharmacokinetic Studies

Savic, Radojka M.; Jonker, Daniël M.; Kerbusch, Thomas; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 711-726, 2007

• DOI for Implementation of a Transit Compartment Model for Describing Drug Absorption in Pharmacokinetic Studies

Diagnosing Model Diagnostics

Karlsson, Mats; Savic, Radojka

Part of Clinical Pharmacology and Therapeutics, p. 17-20, 2007

• DOI for Diagnosing Model Diagnostics

Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum

Holford, N; Karlsson, Mats O.

Part of Clinical Pharmacology and Therapeutics, p. 103-105, 2007

• DOI for Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum

An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers

Lönnebo, Anna; Grahnén, Anders; Karlsson, Mats O.

Part of British Journal of Clinical Pharmacology, p. 125-132, 2007

• DOI for An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers

Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys.

Overgaard, Rune V.; Karlsson, Mats; Ingwersen, Steen H.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 559-574, 2007

• DOI for Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys.

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

Langdon, Grant; Gueorguieva, Ivelina; Aarons, Leon; Karlsson, Mats

Part of European Journal of Clinical Pharmacology, p. 485-498, 2007

• DOI for Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG

Joerger, Markus; Huitema, Alwin D R; Richel, Dick J; Dittrich, Christian et al.

Part of Clinical Pharmacokinetics, p. 1051-1068, 2007

Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in paediatric renal transplant candidates

Fanta, Samuel; Jönsson, Siv; Backman, Janne T; Karlsson, Mats O et al.

Part of British Journal of Clinical Pharmacology, p. 772-784, 2007

• DOI for Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in paediatric renal transplant candidates

An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations

Silber, Hanna E; Jauslin, Petra M; Frey, Nicolas; Gieschke, Ronald et al.

Part of Journal of clinical pharmacology, p. 1159-1171, 2007

• DOI for An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations

Optimal adaptive design in clinical drug development: a simulation example

Maloney, Alan; Karlsson, Mats O; Simonsson, Ulrika S H

Part of Journal of clinical pharmacology, p. 1231-1243, 2007

• DOI for Optimal adaptive design in clinical drug development: a simulation example

Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method

Hooker, Andrew C.; Staatz, Christine E; Karlsson, Mats O

Part of Pharmaceutical research, p. 2187-2197, 2007

• DOI for Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method

An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics

Jauslin, Petra M; Silber, Hanna E; Frey, Nicolas; Gieschke, Ronald et al.

Part of Journal of clinical pharmacology, p. 1244-1255, 2007

• DOI for An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib

van Erp, Nielka P; Gelderblom, Hans; Karlsson, Mats O; Li, Jing et al.

Part of Clinical Cancer Research, p. 7394-7400, 2007

• DOI for Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib

Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.

Joerger, Markus; Huitema, Alwin D. R.; Richel, Dick J.; Dittrich, Christian et al.

Part of Clinical Cancer Research, p. 6410-6418, 2007

• DOI for Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.

Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia

Quartino, Angelica; Karlsson, Mats O.; Freijs, Agneta; Jonsson, Niclas et al.

Part of Journal of clinical pharmacology, p. 1014-1021, 2007

• DOI for Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia

Pharmacokinetics of Desmopressin Administrated as an Oral Lyophilisate Dosage Form in Children With Primary Nocturnal Enuresis and Healthy Adults

Østerberg, Ole; Savic, Radojka; Karlsson, Mats; Simonsson, Ulrika et al.

Part of Journal of clinical pharmacology, p. 1204-1211, 2006

• DOI for Pharmacokinetics of Desmopressin Administrated as an Oral Lyophilisate Dosage Form in Children With Primary Nocturnal Enuresis and Healthy Adults

Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs

Kloft, Charlotte; Wallin, Johan; Henningsson, Anja; Chatelut, Etienne et al.

Part of Clinical Cancer Research, p. 5481-5490, 2006

• DOI for Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs
• Download full text (pdf) of Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs

A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function

Viberg, Anders; Lannergård, Anders; Larsson, Anders; Cars, Otto et al.

Part of British Journal of Clinical Pharmacology, p. 297-303, 2006

• DOI for A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function

Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy

Bååthe, Sofie; Hamrén, Bengt; Karlsson, Mats O.; Wollbratt, Maria et al.

Part of Clinical Pharmacokinetics, p. 803-819, 2006

• DOI for Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy

Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog

Äbelö, Angela; Andersson, Magdalena; Holmberg, Ann Aurell; Karlsson, Mats O.

Part of European Journal of Pharmaceutical Sciences, p. 91-101, 2006

• DOI for Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog

A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat

Magnusson, Mats O.; Karlsson, Mats O.; Sandström, Rikard

Part of Pharmacological Research, p. 521-532, 2006

• DOI for A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat

CHS 828 kill tumour cells by inhibiting the nuclear factor-kappa B translocation but unlikely through down-regulation of proteasome

Hassan, Saadia B.; Lövborg, Henrik; Lindhagen, Elin; Karlsson, Mats O. et al.

Part of Anticancer Research, p. 4431-4436, 2006

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors

Li, Jing; Karlsson, Mats O.; Brahmer, Julie; Spitz, Avery et al.

Part of Journal of the National Cancer Institute, p. 1714-1723, 2006

• DOI for CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors

A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.

Latz, Jane E; Karlsson, Mats O; Rusthoven, James J; Ghosh, Atalanta et al.

Part of Cancer Chemother Pharmacol, p. 412-26, 2006

Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.

Sandström, M; Lindman, H; Nygren, P; Johansson, M et al.

Part of Cancer Chemother Pharmacol, p. 143-56, 2006

Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.

Latz, Jane E; Rusthoven, James J; Karlsson, Mats O; Ghosh, Atalanta et al.

Part of Cancer Chemother Pharmacol, p. 427-35, 2006

A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat.

Magnusson, Mats O; Karlsson, Mats O; Sandström, Rikard

Part of Pharm Res, p. 521-32, 2006

Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.

Zingmark, Per-Henrik; Kågedal, Matts; Karlsson, Mats O

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 261-281, 2005

• DOI for Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.

Pharmacokinetics of ximelagatran and relationship to clinical response in acute vein thrombosis

Cullberg, Marie; Eriksson, Ulf G.; Wåhlander, Karin; Eriksson, Henry et al.

Part of Clinical Pharmacology and Therapeutics, p. 279-290, 2005

• DOI for Pharmacokinetics of ximelagatran and relationship to clinical response in acute vein thrombosis

Model describing the relations between pharmacokinetics and hematological toxicity of the epirubicin-docetaxel regimen in breast cancer

Sandström, Marie; Lindman, Henrik; Nygren, Peter; Lidbrink, Elisabet et al.

Part of Journal of Clinical Oncology, p. 413-421, 2005

• DOI for Model describing the relations between pharmacokinetics and hematological toxicity of the epirubicin-docetaxel regimen in breast cancer

Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo

Hassan, Saadia Bashir; Dhar, Sumeer; Sandström, Marie; Arsenau, Dzmitry et al.

Part of Cancer Chemotherapy and Pharmacology, p. 47-54, 2005

• DOI for Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo

Pharmacokinetic-Pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model

Friberg, Lena; Hassan, Saadia Bashir; Lindhagen, Elin; Larsson, Rolf et al.

Part of European Journal of Pharmaceutical Sciences, p. 163-173, 2005

• DOI for Pharmacokinetic-Pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model

Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug

Jönsson, Siv; Karlsson, Mats O.

Part of European Journal of Pharmaceutical Sciences, p. 123-132, 2005

• DOI for Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug

Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke

Jönsson, Siv; Cheng, Yi-Fang; Edenius, Charlotte; Lees, Kennedy R. et al.

Part of Clinical Pharmacokinetics, p. 863-878, 2005

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.

Henningsson, Anja; Marsh, Sharon; Loos, Walter J; Karlsson, Mats O et al.

Part of Clin Cancer Res, p. 8097-104, 2005

Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.

Sandström, M; Lindman, Henrik; Nygren, Peter; Lidbrink, E et al.

Part of J Clin Oncol, p. 413-21, 2005

Pharmacokinetic/pharmacodynamic modelling in oncological drug development.

Karlsson, Mats O; Anehall, Therese; Friberg, Lena E; Henningsson, Anja et al.

Part of Basic Clin Pharmacol Toxicol, p. 206-11, 2005

A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction.

Gordi, Toufigh; Xie, Rujia; Huong, Nguyen V; Huong, Dinh X et al.

Part of Br J Clin Pharmacol, p. 189-98, 2005

Application of population pharmacokinetics to cladribine.

Lindemalm, Synnöve; Savic, Radojka M; Karlsson, Mats O; Juliusson, Gunnar et al.

Part of BMC Pharmacol, p. 4, 2005

Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug.

Jönsson, Siv; Karlsson, Mats O

Part of Eur J Pharm Sci, p. 123-32, 2005

Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.

Jönsson, Siv; Cheng, Yi-Fang; Edenius, Charlotte; Lees, Kennedy R et al.

Part of Clin Pharmacokinet, p. 863-78, 2005

Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model.

Friberg, Lena E; Hassan, Saadia B; Lindhagen, Elin; Larsson, Rolf et al.

Part of Eur J Pharm Sci, p. 163-73, 2005

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

van Kesteren, Charlotte; Zandvliet, Anthe S; Karlsson, Mats O; Mathôt, Ron A A et al.

Part of Invest New Drugs, p. 225-34, 2005

Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.

Cullberg, Marie; Eriksson, Ulf G; Wåhlander, Karin; Eriksson, Henry et al.

Part of Clin Pharmacol Ther, p. 279-90, 2005

Factors influencing the choice of optimal individualized dosing strategies targeting a drug concentration or effect

Jönsson, Siv; Matolcsi, Katalin; Mentré, France; Karlsson, Mats O.

Part of AAPS PharmSci, 2004

The back-step method: method for obtaining unbiased population parameter estimates for ordered categorical data

Kjellsson, Maria C.; Jönsson, Siv; Karlsson, Mats O.

Part of AAPS Journal, p. 13-22, 2004

• DOI for The back-step method: method for obtaining unbiased population parameter estimates for ordered categorical data

Pharmacokinetic/pharmacodynamic models for the depletion of Vβ5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS

Zingmark, Per-Henrik; Edenius, Charlotte; Karlsson, Mats O.

Part of British Journal of Clinical Pharmacology, p. 378-389, 2004

• DOI for Pharmacokinetic/pharmacodynamic models for the depletion of Vβ5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS

Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM or NLMIXED

Jönsson, Siv; Kjellsson, Maria C.; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 299-320, 2004

• DOI for Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM or NLMIXED

Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability

Kerbusch, Thomas; Wählby, Ulrika; Milligan, Peter A; Karlsson, Mats O

Part of British Journal of Clinical Pharmacology, p. 639-652, 2003

• DOI for Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability

Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients

Zingmark, Per-Henrik; Ekblom, Marianne; Odergren, Tomas; Ashwood, Tim et al.

Part of British Journal of Clinical Pharmacology, p. 173-183, 2003

• DOI for Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients

Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia

Lindemalm, Synnove; Liliemark, Jan; Gruber, Astrid; Eriksson, Staffan et al.

Part of Haematologica, p. 324-332, 2003

Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial

Hornestam, Björn; Jerling, Markus; Karlsson, Mats O; Held, Peter

Part of European Journal of Clinical Pharmacology, p. 747-755, 2003

• DOI for Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial

Mechanistic models for myelosuppression

Friberg, Lena E; Karlsson, Mats O

Part of Investigational new drugs, p. 183-194, 2003

• DOI for Mechanistic models for myelosuppression

A rational approach for selection of optimal covariate-based dosing strategies

Jönsson, Siv; Karlsson, Mats O

Part of Clinical Pharmacology and Therapeutics, p. 7-19, 2003

• DOI for A rational approach for selection of optimal covariate-based dosing strategies

Population pharmacokinetics of levosimendan in patients with congestive heart failure

Jonsson, E Niclas; Antila, Saila; McFadyen, Lynn; Lehtonen, Lasse et al.

Part of British Journal of Clinical Pharmacology, p. 544-551, 2003

• DOI for Population pharmacokinetics of levosimendan in patients with congestive heart failure

Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients

Henningsson, Anja; Sparreboom, Alex; Sandström, Marie; Freijs, Agneta et al.

Part of European Journal of Cancer, p. 1105-1114, 2003

• DOI for Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients

The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs.

Agerso¸, Henrik; Koechling, Wolfgang; Knutsson, Magnus; Hjortkjaer, Rolf et al.

Part of European Journal of Pharmaceutical Sciences, p. 335-340, 2003

• DOI for The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs.

Variable Expression of CYP and Pgp Genes in the Human Small Intestine

Lindell, Monica; Karlsson, Mats O.; Lennernäs, Hans; Påhlman, Lars et al.

Part of European Journal of Clinical Investigation, p. 493-499, 2003

• DOI for Variable Expression of CYP and Pgp Genes in the Human Small Intestine

Irinotecan pathway genotype analysis to predict pharmacokinetics

Mathijssen, Ron H J; Marsh, Sharon; Karlsson, Mats O; Xie, Rujia et al.

Part of Clinical Cancer Research, p. 3246-3253, 2003

A rational approach for selection of optimal covariate-based dosing strategies

Jönsson, Siv; Karlsson, Mats O.

Part of Clinical Pharmacology and Therapeutics, p. 7-19, 2003

• DOI for A rational approach for selection of optimal covariate-based dosing strategies

Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients

Zingmark, Per-Henrik; Ekblom, Marianne; Odergren, Tomas; Ashwood, Tim et al.

Part of British Journal of Clinical Pharmacology, p. 173-183, 2003

• DOI for Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients

Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea

Xie, Rujia; Mathijssen, Ron H J; Sparreboom, Alex; Verweij, Jaap et al.

Part of Clinical Pharmacology and Therapeutics, p. 265-275, 2002

• DOI for Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea

Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria.

Svensson, Ulrika S H; Alin, Hassan; Karlsson, Mats O; Bergqvist, Yngve et al.

Part of European Journal of Clinical Pharmacology, p. 339-351, 2002

• DOI for Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria.

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

Friberg, Lena E.; Henningsson, Anja; Maas, Hugo; Nguyen, Laurent et al.

Part of Journal of Clinical Oncology, p. 4713-4721, 2002

• DOI for Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

A Phase I Study of CHS 828 in Patients with Solid Tumor Malignancy

Hovstadius, Peter; Larsson, Rolf; Lindhagen, Elin; Skov, Torsten et al.

Part of Clinical Cancer Research, p. 2843-2850, 2002

Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole

Äbelö, Angela; Holstein, Björn; Eriksson, Ulf G.; Gabrielsson, Johan et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 365-382, 2002

• DOI for Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole

Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs

Friberg, Lena E.; Henningsson, Anja; Maas, Hugo; Nguyen, Laurent et al.

Part of Journal of Clinical Oncology, p. 4713-4721, 2002

• DOI for Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs

Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

Wählby, Ulrika; Jonsson, E Niclas; Karlsson, Mats O

Part of AAPS PharmSci, 2002

Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease

Cullberg, Marie; Eriksson, Ulf G.; Larsson, Marita; Karlsson, Mats O.

Part of British Journal of Clinical Pharmacology, p. 71-79, 2001

• DOI for Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease

Mechanism-based pharmacokinetic model for paclitaxel

Henningsson, Anja; Karlsson, Mats O.; Viganò, Lucia; Gianni, Luca et al.

Part of Journal of Clinical Oncology, p. 4065-4073, 2001

Model for time dependency of the cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action

Hassan, Saadia Bashir; Jonsson, Elin; Larsson, Rolf; Karlsson, Mats O.

Part of Journal of Pharmacology and Experimental Therapeutics, p. 1140-1147, 2001

A hollow fiber model for in vitro studies of cytotoxic compounds: Activity of the cyanoguanidine CHS 828

Hassan, Saadia Bashir; de la Torre, Manuel; Nygren, Peter; Karlsson, Mats O. et al.

Part of Anti-Cancer Drugs, p. 33-42, 2001

Pharmacodynamic modelling of reversible gastric acid pump inhibition in dog and man

Äbelö, Angela; Gabrielsson, Johan; Holstein, Björn; Eriksson, Ulf G et al.

Part of European Journal of Pharmaceutical Sciences, p. 339-346, 2001

• DOI for Pharmacodynamic modelling of reversible gastric acid pump inhibition in dog and man

Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats

Simonsen, Lena E.; Wählby, Ulrika; Sandström, Marie; Freijs, Agneta et al.

Part of Anticancer Research, p. 1519-1525, 2000

Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats

Jonsson, Elin; Friberg, Lena E.; Karlsson, Mats O.; Hassan, Saadia Bashir et al.

Part of Cancer Chemotherapy and Pharmacology, p. 493-500, 2000

• DOI for Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats

A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog

Äbelö, Angela; Eriksson, Ulf G; Karlsson, Mats O.; Larsson, Håkan et al.

Part of Journal of Pharmacology and Experimental Therapeutics, p. 662-669, 2000

Lactational exposure and neonatal kinetics of methylmercury and inorganic mercury in mice.

Sundberg, J; Jönsson, S; Karlsson, M O; Oskarsson, A

Part of Toxicology and Applied Pharmacology, p. 160-9, 1999

• DOI for Lactational exposure and neonatal kinetics of methylmercury and inorganic mercury in mice.

The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination

Olsson Gisleskog, Per; Hermann, David; Hammarlund-Udenaes, Margareta; Karlsson, Mats O

Part of British Journal of Clinical Pharmacology, p. 53-58, 1999

• DOI for The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination

Kinetics of methylmercury and inorganic mercury in lactating and nonlactating mice.

Sundberg, J; Jönsson, S; Karlsson, M O; Hallén, I P et al.

Part of Toxicology and Applied Pharmacology, p. 319-29, 1998

• DOI for Kinetics of methylmercury and inorganic mercury in lactating and nonlactating mice.

Toxicokinetics of lead in lactating and nonlactating mice.

Hallén, I P; Jönsson, Siv; Karlsson, M O; Oskarsson, A

Part of Toxicology and Applied Pharmacology, p. 342-7, 1996

• DOI for Toxicokinetics of lead in lactating and nonlactating mice.

Kinetic observations in neonatal mice exposed to lead via milk.

Palminger Hallén, I; Jönsson, S; Karlsson, M O; Oskarsson, A

Part of Toxicology and Applied Pharmacology, p. 13-8, 1996

Utility of ecarin clotting time, an ex vivo coagulation test, for pharmacokinetic analysis of the direct thrombin inhibitor melagatran

Cullberg, Marie; Wählby, Ulrika; Karlsson, Mats O.; Eriksson, Ulf G.

Population pharmacokinetics of tacrolimus in paediatric liver transplant recipients: a model to describe early post-transplantation apparent clearance

Wallin, Johan; Wilczek, Henryk; Nydert, Per S.; Karlsson, Mats O. et al.

Part of American Journal of Transplantation

• Download full text (pdf) of Population pharmacokinetics of tacrolimus in paediatric liver transplant recipients: a model to describe early post-transplantation apparent clearance

Predictive performance of internal and external validation procedures

Baverel, Paul G; Karlsson, Kristin E; Karlsson, Mats O

Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients

Abrantes, João; Solms, Alexander; Garmann, Dirk; Nielsen, Elisabet I. et al.

Item Response Theory-Informed Total Score Analysis

Wellhagen, Gustaf J.; Ueckert, Sebastian; Kjellsson, Maria C.; Karlsson, Mats O.

Covariate modeling in pharmacometrics: General points for consideration

Sanghavi, Kinjal; Ribbing, Jakob; Rogers, James A.; Ahmed, Mariam A. et al.

Part of CPT, p. 710-728, 2024

• DOI for Covariate modeling in pharmacometrics: General points for consideration
• Download full text (pdf) of Covariate modeling in pharmacometrics: General points for consideration

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis

Hermann, Robert; Karlsson, Mats O; Novakovic, Ana M.; Terranova, Nadia et al.

Part of Clinical Pharmacokinetics, p. 283-297, 2019

• DOI for The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
• Download full text (pdf) of The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis

Open innovation: Towards sharing of data, models and workflows

Conrado, Daniela J.; Karlsson, Mats O; Romero, Klaus; Sarr, Celine et al.

Part of European Journal of Pharmaceutical Sciences, 2017

• DOI for Open innovation: Towards sharing of data, models and workflows

An Integrated Model for the Glucose-Insulin System

Silber, Hanna E.; Jauslin, Petra M.; Frey, Nicolas; Karlsson, Mats O.

Part of Basic & Clinical Pharmacology & Toxicology, p. 189-194, 2010

• DOI for An Integrated Model for the Glucose-Insulin System

Model-Based Neutrophil-Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome with Different Types and Amounts of Information

Wallin, Johan E.; Friberg, Lena E.; Karlsson, Mats O.

Part of Basic & Clinical Pharmacology & Toxicology, p. 234-242, 2010

• DOI for Model-Based Neutrophil-Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome with Different Types and Amounts of Information

Incorporating Physiological and Biochemical Mechanisms into Pharmacokinetic-Pharmacodynamic Models: A Conceptual Framework

Dahl, Svein G.; Aarons, Leon; Gundert-Remy, Ursula; Karlsson, Mats O. et al.

Part of Basic & Clinical Pharmacology & Toxicology, p. 2-12, 2010

• DOI for Incorporating Physiological and Biochemical Mechanisms into Pharmacokinetic-Pharmacodynamic Models: A Conceptual Framework

Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis

Eriksson, Ulf G; Mandema, Jaap W; Karlsson, Mats O; Frison, Lars et al.

Part of Clinical Pharmacokinetics, p. 687-701, 2003

Pharmacokinetic-pharmacodynamic modeling of the schedule-dependent effect of CHS 828 in a rat hollow fiber model

Friberg, Lena E.; Hassan, Saadia B.; Jonsson, Elin; Larsson, Rolf et al.

Expression of UDP-Glucuronosyltransferase Genes (UGTs) in Human Duodenum

Lindell, Monica; Karlsson, Mats O.; Påhlman, Lars; Lennernäs, Hans et al.

Application of a combined effect-compartment and binding model for gastric acid inhibition of AR-HO47108, a reversible gastric acid proton pump inhibitor, and its active metabolite AR-HO47116, in the dog

Äbelö, Angela; Holstein, Björn; Andersson, Magdalena; Karlsson, Mats O

Does the novel anticancer agent CHS 828 induces tumor cell death by inhibiting the transcription factor NF-kB translocation through down regulation of the proteasome?

Hassan, Saadia Bashir; Lövborg, Henrik; Lindhagen, Elin; Karlsson, Mats O et al.

Population Pharmacokinetic Model for Cremophor EL

Henningsson, Anja; Sparreboom, Alex; Loos, Walter J.; Verweij, Jaap et al.

Comparing the differential drug effect model to the proportional odds model

Zingmark, Per-Henrik; Kjellsson, Maria C.; Jonsson, E. Niclas; Karlsson, Mats O.

The time course of the biomarkers body temperature, serum amyloid A protein (SAA), C-reactive protein (CRP) and interleukin- (IL) 6 during initial treatment with cefuroxime in patients with bacterial infections

Viberg, Anders; Lannergård, Anders; Cars, Otto; Karlsson, Mats O et al.

Individualization of Cefuroxime Dosage using Pharmacodynamic targets, MIC distributions and Minimization of a Risk Function

Viberg, Anders; Cars, Otto; Karlsson, Mats O; Jönsson, Siv

Evaluating the evaluations: resampling methods for determining model appropriateness in pharmacometric data analysis

Lindbom, Lars; Wilkins, Justin J; Frey, Nicolas; Karlsson, Mats O et al.

Ximelagatran in extended secondary prevention of venous thromboembolism: Pharmacokinetics, pharmacodynamics and relationships to clinical events

Cullberg, Marie; Wåhlander, Karin; Lundström, Torbjörn; Wall, Ulrika et al.

A mechanistic model describing the impact of carbamazepine on the pharmacokinetics of clomethiazole and its metabolite NLA-715

Magnusson, Mats O.; Zingmark, Per-Henrik; Fransson, Bo; Karlsson, Mats O. et al.

Pharmacodynamics of enzyme induction attributable to carbamazepine treatment using midazolam, caffeine and digoxin as probe substrates

Magnusson, Mats O.; Dahl, Marja-Liisa; Cederberg, Jonas; Karlsson, Mats O. et al.

A novel covariate search method intended for PKPD models with nonparametric parameter distributions

Baverel, Paul; Savic, Rada; Marshall, Scott; Karlsson, Mats

Modeling of mycobacterial load reveals bedaquiline’s exposure-response relationship in patients with drug-resistant tuberculosis

Svensson, Elin M; Rossenu, Stefaan; Karlsson, Mats O

Optimal Design Applied to Hematological Toxicity-Induced Anticancer Treatment

Vong, Camille; Nyberg, Joakim; Karlsson, Mats O.; Friberg, Lena E. et al.

Multinomial Markov-chain model of sleep architecture in Phase Advanced Subjects

Ernest II, Charles; Bizzotto, Roberto; DeBrota, David J.; Ni, Lan et al.

• Download full text (pdf) of Multinomial Markov-chain model of sleep architecture in Phase Advanced Subjects

Challenges and potential of optimal design in late phase clinical trials through application in Alzheimer’s disease

Ueckert, Sebastian; Andrew, Marilee A.; Karlsson, Mats; Ito, Kaori et al.

Characterization of Anti-Drug Antibody Dynamics Using a Bivariate Mixed Hidden-Markov Model

Brekkan, Ari; Lledo-Garcia, Rocio; Lacroix, Brigitte; Jönsson, Siv et al.

The influence of second-line immuno-therapies on the survival outcome of first-line non-small cell lung cancer atezolizumab IMpower131 study: An application of multistate modeling

Madathil Krishnan, Sreenath; Friberg, Lena; Zhang, Rong; Mercier, Francois et al.

Pharmacodynamic interaction of bedaquiline and delamanid co-administration on QTcF interval prolongation

Tanneau, Lénaïg; Karlsson, Mats; Rosenkranz, Susan L; Cramer, Yoninah S et al.

Assessment of non-linear mixed effect model-based approaches to test for drug effect using simulated data: type I error and power properties.

Chasseloup, Estelle; Tessier, Adrien; Karlsson, Mats

Extension of individual model averaging assessments to unbalanced designs and dose-response.

Chasseloup, Estelle; Li, Xinyi; Karlsson, Mats

Comparative Analysis of Pharmacoeconomic and Pharmacometric Modeling in the Cost-Effectiveness Evaluation of Sunitinib Therapy with Therapeutic Drug Monitoring for Gastrointestinal Stromal Tumors

Centanni, Maddalena; Nijhuis, Janine; Karlsson, Mats; Friberg, Lena